

Alzheimer's Biochemistry and Therapeutic Prospects of Functional Foods-based Strategies



Clinton Ayodeji Akanbi¹, Musbau Adewumi Akanji² and Oluyomi Stephen Adeyemi^{1,*}

¹Department of Biochemistry, Medicinal Biochemistry, Nanomedicine & Toxicology Laboratory, Bowen University, Iwo - 232101, Osun State, Nigeria

²Department of Biochemistry, Kwara State University, Malete, Ilorin, Kwara State, Nigeria

Abstract:

Alzheimer's disease (AD) is a complex and multifactorial neurodegenerative disorder characterized by common pathogenic features, such as the development of amyloid- β ($A\beta$) plaques and the formation of neurofibrillary tangles from hyperphosphorylated tau proteins. Although the cholinergic hypothesis, which focuses on the cognitive role of acetylcholine, remains a fundamental concept, recent studies have reported that neuroinflammation and oxidative stress play pivotal roles in the pathology of AD. Besides these pathways, aging, diverse diseases, environmental factors, and genetic conditions are well-known risk factors for AD. Currently, no disease-modifying treatment exists for AD. The available therapies provide only symptomatic relief and are often associated with adverse side effects. Meanwhile, growing evidence suggests that dietary interventions rich in anti-inflammatory and antioxidant compounds can modulate inflammatory cytokines and neutralize free radicals, thereby offering a promising approach to mitigate AD risk and potentially delay its onset. Future research should focus on developing novel therapeutic strategies that specifically target the restoration of the oxidative-inflammatory balance, moving beyond symptomatic relief to address the key pathological pathways in AD.

Keywords: $A\beta$ plaques, Antioxidants, Inflammation, Neurological disorder, Oxidative stress, Tau proteins.

© 2025 The Author(s). Published by Bentham Open.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: <https://creativecommons.org/licenses/by/4.0/legalcode>. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



CrossMark

Received: June 19, 2025

Revised: September 18, 2025

Accepted: October 23, 2025

Published: December 03, 2025

*Department of Biochemistry, Medicinal Biochemistry, Nanomedicine & Toxicology Laboratory, Bowen University, Iwo - 232101, Osun State, Nigeria; E-mail: yomibowa@yahoo.com

Cite as: Akanbi C, Akanji M, Adeyemi O. Alzheimer's Biochemistry and Therapeutic Prospects of Functional Foods-based Strategies. Open Biochem J, 2025; 19: e1874091X416492. <http://dx.doi.org/10.2174/011874091X416492251129102634>



Send Orders for Reprints to
reprints@benthamscience.net

1. INTRODUCTION

Neurodegenerative diseases are a group of disorders characterized by the progressive loss of neuronal structure or function, which eventually leads to the death of the affected neurons [1]. Among them, Alzheimer's disease (AD) is the most common and accounts for the majority of dementia cases worldwide [2, 3]. Clinically, AD manifests as progressive memory loss, cognitive decline, and difficulty carrying out everyday tasks, all of which harm the quality of life for those affected [3]. As the illness progresses, people frequently need full-time care, which places a tremendous social and financial strain on families and healthcare systems around the globe. Because of this,

AD is not only a significant contributor to morbidity but also a major cause of the global health crisis related to aging populations [4].

From a histological standpoint, AD development is associated with three main neuropathological traits: the formation of neurofibrillary tangles (NFTs), synaptic degeneration, and the buildup of extracellular amyloid plaques, which occurs in the neocortex, hippocampal regions, and other subcortical regions essential to cognitive function [5]. People over 65 are typically affected, and early onset before age 65 is uncommon [6]. The global aging population is experiencing an alarming rise in the prevalence of AD. The World Alzheimer's Report states that 46.8 million individuals globally are

estimated to be affected by AD, and this number is expected to triple by 2050 as the population ages, particularly if interventions are ineffective [7, 8]. Additionally, it has been found that approximately 60-80% of the incidence of AD can be attributed to heritable traits. Of these, there are currently over 40 genetically susceptible loci linked to AD, the strongest of which is the apolipoprotein E (APOE) allele [8].

Although metabolic byproducts are required for physiological function, reactive oxygen species (ROS) can be harmful in excess. ROS can promote oxidative stress, harming every part of the body, especially the central nervous system, and compromising mitochondrial function [9]. An increasing amount of research points to the role of oxidative stress in AD development by facilitating the deposition of A β , tau hyperphosphorylation, and the subsequent loss of neurons and synapses [10]. Concurrently, persistent neuroinflammation, which is defined by the release of pro-inflammatory cytokines and the activation of microglia, worsens neuronal damage and advances the course of the disease [11]. Recent data indicate that inflammation and oxidative stress work together to create a vicious cycle that exacerbates AD neurodegeneration [12].

Despite decades of research, there is still no cure for AD [13]. Current therapies, like N-Methyl-D-Aspartate (NMDA) receptor antagonists and acetylcholinesterase inhibitors, only provide modest symptom reduction and frequently have serious adverse effects [3, 14]. In the meantime, attempts to directly target tau pathology and A β have not yet shown significant progress in clinical trials [15]. Consequently, there is increasing interest in investigating complementary or alternative approaches that can modulate the biochemical mechanisms underlying AD. In recent years, natural bioactive substances with anti-inflammatory and antioxidant properties, such as quercetin, carotenoids, kaempferol, resveratrol, and curcumin, have gained attention. These substances have the potential to act at several stages of the disease cascade by lowering oxidative damage, managing neuroinflammation, and maintaining neuronal function, in contrast to single-target pharmacological agents [16-18].

Although oxidative stress and neuroinflammation in AD have been covered in great detail in earlier reviews, these mechanisms are frequently addressed independently or primarily focus on synthetic pharmacological interventions. Furthermore, despite the growing awareness of the oxido-inflammatory balance, there is still a lack of comprehensive research on how functional foods can concurrently alter oxidative and inflammatory pathways, providing a multitarget and safer substitute. With a focus on functional food-based interventions that target the oxido-inflammatory balance as a promising avenue for managing AD, this review highlights the biochemical mechanisms by which functional foods exert neuroprotective effects in AD, while also summarizing the key preclinical findings and existing clinical trial results to provide an integrative synopsis of their translational potential.

2. METHODS

This review included a search for relevant articles from online databases (Google Scholar, PubMed, ScienceDirect, Scopus, and Web of Science). Articles published until 2025 were considered. Articles published in the English language between 2010 and 2025 were identified and extracted using the search terms "biochemistry of Alzheimer's", "Alzheimer's and amyloid beta", "tau protein and AD", "cholinergic hypothesis", "oxidative damage and inflammation in AD", "risk factors in AD", and "therapeutic strategies in AD". The inclusion criteria were relevance to AD biochemistry, peer-reviewed articles (original research, systematic reviews, or meta-analyses), and availability of full text. Articles were excluded if they lacked full-text access, were not directly related to the biochemistry of AD, were published outside the specified timeframe, or lacked scientific rigor. A total of 287 articles were initially retrieved, with 77 excluded, resulting in the final set used in this review.

3. AD NEUROPATHOLOGY

3.1. Amyloid- β (A β) Peptide

The A β peptide consists of 42 amino acids and originates from the amyloid- β precursor protein (APP). On chromosome 21, there is a gene encoding APP [14]. β -, γ -, and α -secretases break down APP at different domains. β -Secretase cleaves APP first, and γ -secretase cleaves it again, producing A β peptides of varying lengths, such as A β 40 and A β 42, which differ in the number of residues; A β 42 has two additional residues at its C-terminus compared to A β 40. Most A β plaques in AD are formed by the A β 42 isoform, although some plaques exclusively contain this isoform [19].

The normal function of APP involves regulating synaptic plasticity, cell signaling, and neuronal growth. It is also linked to the restoration of damaged neurons, particularly under stress or injury conditions [20]. AD is primarily caused by the pathological cleavage of APP by β - and γ -secretases, which results in the formation of A β peptides [19]. One could argue that the main problem in AD pathogenesis may be the disruption of APP's normal physiological roles, rather than only the accumulation of its breakdown products (A β plaques), even though A β aggregation is a hallmark of AD. This is because the physiological functions of APP are critical for maintaining neuronal health and functionality [21]. These functions may be compromised long before A β plaques accumulate to pathological levels due to dysregulated APP processing or APP gene mutations [22]. Additionally, the buildup of A β plaques may not be the sole cause of neurodegeneration but rather a consequence of a fundamental impairment in APP function [23].

In healthy neurons, α - and γ -secretase enzymes process APP along the non-amyloidogenic pathway (Fig. 1) [24]. This reaction produces soluble polypeptides that can later be recycled and degraded in the cell. β - and γ -secretases can also process APP through the amyloidogenic pathway, as shown in Fig. (1), generating an inso-

luble peptide known as A β . A β peptides aggregate to form plaques that are detrimental to neuronal cells. At least three major cellular problems may arise when A β plaques accumulate. A β plaques may disrupt communication between healthy neurons, and when neuronal signaling is impaired, the brain suffers damage and loses specific functions [25]. The brain contains two major A β species—A β 42 and A β 40. Although A β 40 is more abundant in soluble form, A β 42 is the primary component of A β plaques [26].

The brain's primary β -secretase is BACE1 (β -Site APP-Cleaving Enzyme 1). Neurotoxic forms of A β are generated when BACE1 cleaves APP, producing soluble APP β (sAPP β) and C99 fragments [27]. The γ -secretase complex then cleaves C99 to produce A β . Furthermore, in early-onset AD, mutations in presenilin-1 (PSEN1) and presenilin-2 (PSEN2) alter γ -secretase activity, increasing

the A β 42/A β 40 ratio by influencing the proteolytic function of γ -secretase [5].

3.2. Fibrillogenesis- Role of A β Plaque in AD

A β monomers combine to form oligomers, protofibrils, and amyloid fibrils, among other assemblies (Fig. 2). Whereas amyloid oligomers are soluble and can disperse throughout the brain, amyloid fibrils are larger, insoluble, and can further assemble into A β plaques [24]. A β monomers can exist as soluble oligomers capable of spreading within the brain or as large, insoluble fibrils that accumulate to form plaques. Because A β is involved in neurotoxicity and neuronal function, the buildup of dense plaques in the cerebral cortex and hippocampus can result in cognitive impairment, damage to axons and dendrites, synaptic loss, and stimulation of microglia and astrocytes [3].




Fig. (1). Dual pathways of APP cleavage (non-amyloidogenic and amyloidogenic). This figure, adapted from [24], shows how the APP is processed by proteases at the cell membrane through both amyloidogenic and non-amyloidogenic pathways. APP is broken down by α -secretase at the extracellular domain in the non-amyloidogenic pathway, producing sAPP α and the membrane-bound CTF α (C83), which is then processed by γ -secretase inside the lipid bilayer to yield the P3 peptide and the AICD. AICD and A β peptides, particularly A β 40 and A β 42, are released when γ -secretase cleaves APP at a similar extracellular site in the amyloidogenic pathway, resulting in sAPP β and CTF β (C99). These occurrences highlight the membrane localization of APP metabolism [14, 19, 24].

Abbreviations: APP: Amyloid precursor protein; sAPP α : Soluble amyloid precursor protein-alpha; CTF α (C83): C-terminal fragment alpha (83 amino acids); P3: Peptide 3; AICD: APP intracellular domain; A β : Amyloid-beta; A β 40: 40-amino-acid isoform of amyloid-beta; A β 42: 42-amino-acid isoform of amyloid-beta; sAPP β : Soluble amyloid precursor protein-beta; CTF β (C99): C-terminal fragment beta (99 amino acids).

The formation of short, flexible, irregular protofibrils is the first step in fibrillogenesis. These protofibrils further aggregate to form a variety of oligomeric species, which eventually mature and elongate into insoluble fibrils with a β -strand-repeating substructure oriented perpendicular to the fiber axis, as described in Fig. (2) [28]. When A β aggregates extracellularly to form fibrils, it becomes resistant to proteolytic cleavage. A β monomers can assemble into oligomers and higher-order structures, with the β -sheet conformation allowing them to exist in a dynamic equilibrium of multiple structural states. To form unstable, soluble A β oligomers, A β 40—or the more aggregation-prone A β 42—first misfolds and then aggregates with additional monomers. Oligomeric amyloid represents an intermediary phase in the development of mature fibrils. AD is characterized by the accumulation of amyloid fibrils in extracellular plaques [26].

3.3. A β Interactions with Receptors

The cell membrane contains significant ion channels that maintain Ca²⁺ ion homeostasis within the cell. Voltage-gated Ca²⁺ channels, including L-type, P-type, and Q-type, mediate the transport of these ions. Among these, the L-type channel is particularly relevant in AD due to its stimulatory capacity. When A β binds to specific synaptic receptors, it can activate these receptors, potentially

leading to the opening of L-type Ca²⁺ channels. The relevance of the L-type channel lies in its ability to facilitate a significant influx of Ca²⁺ ions into the cell, which can influence various cellular processes. In the context of AD, excessive activation of these channels can contribute to neuronal dysfunction and cell death. However, in other situations, the cell may internalize and degrade the receptor-A β complex. This process can result in an increased concentration of A β peptide inside the cell, which may further disrupt cellular functions and contribute to the pathological effects observed in AD [29]. Additionally, A β can form complexes with different NMDA receptors. The NMDA receptor-A β interaction modifies the glutamate balance in neurons, resulting in excitotoxicity. This condition, known as excitotoxicity, occurs when excessive glutamate, an excitatory amino acid, becomes toxic to neurons [30]. As a result of this interaction, NMDA receptors become overactivated, leading to increased glutamate concentration in the synaptic cleft and causing excessive calcium influx. The resulting glutamate dysregulation increases the brain's excitatory signaling, overtaxing neurons and making them more susceptible to damage [31]. Thus, glutamate imbalance and the subsequent excitotoxicity play a pivotal role in exacerbating neurodegeneration in AD [5].




Fig. (2). The aggregation and fibril formation of A β peptides. This figure, adapted from [28], depicts the sequential aggregation of A β peptides following APP processing. In the extracellular space, A β monomers are first produced and released, where they self-assemble into soluble oligomers. After interacting with the neuronal cell surface, these oligomers further assemble into linear protofibrils. A β plaques are formed when these protofibrils lengthen and solidify into insoluble fibrils that eventually accumulate close to neuronal membranes. AD pathology is significantly influenced by the accumulation of these aggregates at the cell surface, which may compromise membrane integrity and cellular function [26, 28].

Abbreviations: A β : Amyloid-beta; APP: Amyloid precursor protein; AD: Alzheimer's disease.

The fibrillogenesis of A β oligomers depends on their binding to the ApoE isoform. Compared to the A β -ApoE3 complex, the A β -ApoE4 complex forms fewer stable complexes with A β , likely due to ApoE4's lower lipid content. ApoE4 also shows lower affinity for the LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) receptor and has a reduced rate of receptor endocytosis. Consequently, A β oligomers bound to ApoE4 undergo less receptor endocytosis and lysosomal degradation. Additionally, ApoE4 more effectively stabilizes extracellular amyloid oligomers, promoting their accumulation and the growth of A β plaques [29]. The α 7-nicotinic acetylcholine receptor (α 7-nAChR) also plays a crucial role in AD, characterized by hyperphosphorylated tau protein and A β accumulations. A β binds to α 7-nAChRs with high affinity, activating or inhibiting the receptor depending on the concentration. Evidence suggests α 7-nAChRs are neuroprotective, reducing A β toxicity. However, the colocalization of A β , α 7-nAChRs, and A β plaques implicates potential neurodegenerative effects [32].

3.4. Tau Protein

Tau protein binds to microtubules and belongs to the group of natively unfolded microtubule-associated proteins (MAPs). Its N-terminal region, proline-rich domain, microtubule-binding domain, and C-terminal region function in microtubule assembly, stabilization, and regulation of motor-driven axonal transport. Although tau is primarily found in neuronal axons, it may also be physiologically significant in dendrites [33, 34].

The tau protein is encoded by the *microtubule-associated protein tau* (MAPT) gene, which is predominantly expressed in neurons [35, 36]. An alternative splicing mechanism controls its expression during development, and the adult human brain contains six distinct isoforms. The alternative splicing of exons 2, 3, and 10 during tau transcription and translation produces these isoforms. It is important to remember that exon 3 can only be translated when exon 2 is present. The microtubule-binding domain's second repeat region (R2) is encoded by exon 10, and the N1 and N2 regions are encoded by exons 2 and 3 [34].

3.5. Modifications of Tau

It has long been known that tau's post-translational modifications alter its protein function and fuel neurodegeneration [37].

3.5.1. Hyperphosphorylation of Tau

The quantity of hyperphosphorylated tau in the AD brain is two to three times higher than in the healthy brain. Tau hyperphosphorylation is a result of the interaction between kinases and phosphatases. Proline-directed protein kinases (PDPKs) modify tau by phosphorylating it primarily on serine and threonine residues adjacent to proline. Tyrosine residues such as Tyr394 and Tyr18, which are found in Paired Helical Filaments (PHFs) in the brains of AD patients, are also phosphorylation targets. Tau can additionally be phosphorylated by several non-PDPKs, including casein

kinase 1 (CK1), microtubule affinity-regulated kinase 110 (MARK p110), calcium/calmodulin-activated protein kinase II (CaMK II), and protein kinase A (PKA) [38].

Tau dephosphorylation has been linked to protein phosphatase 1 (PP1), PP2A, PP2B, PP2C, and PP5, with PP2A being the primary phosphatase among them. Since hyperphosphorylation and aggregation are both elevated in AD, hyperphosphorylated tau may cause pathology through several mechanisms. For example, it may cause tau to mis-sort from axons to the somatodendritic compartment, resulting in synaptic dysfunction, impaired proteasome function, and tau aggregation [38, 39].

3.6. The Role of a Higher Amount of Tau Protein in AD

A rise in tau can be caused by a deficiency in tau degradation, an increase in the translation of tau protein, or an increase in the transcription of the MAPT gene. Currently, the working hypothesis is that inadequate protein degradation, rather than increased tau expression, is the primary cause of tau accumulation. When tau protein is not broken down by the body, it can be phosphorylated by different kinases or undergo other modifications that lead to the buildup of modified tau. When these altered forms accumulate in neurons, some of them become toxic and can cause neuronal degeneration in AD [40].

Diseases known as tauopathies are caused by malfunctions in the tau protein, either through a decline in function or the acquisition of toxic function. Tau undergoes various post-translational modifications under physiological conditions, which affect the structure, functionality, and intracellular processing of the protein. Since phosphorylation is thought to play a key role in tau pathology, it has drawn the most attention. It has been suggested that cytosolic accumulation of phospho-tau occurs before tau aggregation, which causes neuronal degeneration in AD and tauopathies [36, 40].

The dynamics and equilibrium of tau-microtubule binding are significantly influenced by its aberrant post-translational modifications, such as acetylation and hyperphosphorylation. After aggregating in the cytosol, these changes alter its conformation, resulting in the formation of NFTs. The formation of NFTs is more closely associated with cognitive decline than the distribution of senile plaques, an additional pathological feature of AD formed by polymorphous A β protein deposits [38].

Axons, dendrites, and neuronal perikaryon cytoplasm are all affected when the tau protein that is not normally phosphorylated begins clumping together in filaments known as NFTs, which are primarily composed of bundles of Paired Helical Filaments (PHFs). This leads to the loss of tubulin-associated proteins and cytoskeletal microtubules in the neuronal perikaryon cytoplasm. However, both adult and fetal brains exhibit normal tau phosphorylation without aggregation into filaments. Moreover, under physiological conditions, recombinant non-phosphorylated tau forms filaments when combined with various polyanions, indicating that pathological

filament formation is promoted by mechanisms other than aberrant phosphorylation [3-41].

Tau's intrinsic disorder is primarily caused by the high concentration of basic amino acid residues in its primary structure. Therefore, phosphorylation or interactions with anionic species are required to neutralize the excess positive charge on tau molecules. Tau filaments are induced to form by anions such as taurine, docosahexaenoic acid, and arachidonic acid. To induce the formation of tau filaments, poly-L-glutamic acid and heparin—powerful polyanionic inducers of tau fibrillization—can also be used to promote tau aggregation. Of these, heparin is the most frequently studied [42].

3.7. Role of A β on Neurofibrillary Degeneration

NFTs and extracellular amyloid deposits are the two main neuropathological elements associated with AD. NFTs arise due to the abnormal phosphorylation of tau isoforms, which subsequently accumulate and aggregate into fibrils within neurons. NFTs influence the cholinergic system in AD, and there is a substantial relationship between cognitive deficits and their spatiotemporal distribution. Furthermore, there is a correlation between the advancement of tau pathology and elevated levels of brain A β peptides, as well as the disappearance of APP metabolites [43].

A growing body of data indicates that APP metabolism controls tau expression by inhibiting β -secretase, which lowers intracellular tau protein (cleavage by β -secretase releases a soluble APP fragment into the extracellular space). The intersection of tau metabolism and APP may be found in the cellular protein homeostasis systems that are controlled by autophagy and the endosome/lysosome pathways [44, 45]. These alterations are shown in Fig. (3) (adapted from [46, 47]), which illustrates characteristic histopathological changes, including amyloid deposits, neuritic plaques, and tau-associated neurofibrillary tangles.

3.8. Cholinergic Neurons in AD

A neurotransmitter called acetylcholine (ACh), released by cholinergic neurons, plays a central role in signal transduction mechanisms related to memory and learning. The cholinergic theory—the earliest proposed explanation for Alzheimer's disease (AD) pathophysiology—arose from observations that cholinergic neurons are involved in cognitive decline and behavioral impairments associated with AD. Abnormalities in central cholinergic function can contribute to apoptosis, neuroinflammation, aberrant tau phosphorylation, and other pathological processes [48].




Fig. (3). Histopathological images depicting the pathogenesis of AD. This figure, adapted from [46], illustrates the histopathological changes characteristic of AD, including: (A) Congo red-stained amyloid plaques in the neuropil, which are used to identify amyloid deposits [46]; (B) Neuritic plaque with dystrophic neurites revealed by Bodian stain, which accentuates neuronal processes and structural abnormalities [47]; and (C) neurofibrillary tangles (big arrows) and neuropil threads (small arrows), which are also shown by Bodian stain, indicating the presence of pathological filamentous tau aggregates within neurons [46, 47].

Cholinergic neurons in the basal forebrain are particularly vulnerable to neurofibrillary degeneration and neurofibrillary tangle (NFT) formation. Reduced activity of choline acetyltransferase (the enzyme responsible for ACh synthesis) (Fig. 4) [49] correlates with increasing neuritic plaque burden in AD brains, suggesting a link between cholinergic dysfunction and A β pathology. Animal studies support this connection, showing that cholinergic loss is associated with increased A β deposition and elevated levels of hyperphosphorylated tau in the cortex and hippocampus [50]. Additional contributors to cholinergic impairment include reductions in nicotinic and muscarinic (M2) acetylcholine receptors located on presynaptic cholinergic terminals. These receptor deficits diminish glutamate levels and D-aspartate uptake across multiple cortical regions in AD [3].

Although cholinergic dysfunction in AD is most pronounced in regions critical for learning and memory—particularly the basal forebrain—other cholinergic systems (*e.g.*, those in anterior horn cells and motor brainstem nuclei) appear to be comparatively preserved [51]. Electrophysiological studies indicate that peripheral nerve conduction and motor evoked potentials do not differ significantly between AD patients and healthy controls, suggesting intact motor neuron function. This preservation may be due to differing neurotransmitter dependencies; for instance, the corticospinal tract primarily uses glutamate rather than acetylcholine, rendering it less susceptible to cholinergic deficits characteristic of AD [52]. Emerging evidence also suggests reduced vulnerability of cholinergic neurons in these motor-related regions, though their precise contribution to AD pathology remains unclear [53].




Fig. (4). Cholinergic system alterations in AD. This figure, reproduced from [49], shows neurotransmitter release and receptor changes. ACh is synthesized by the enzyme ChAT within the presynaptic neuron. Once released into the synaptic cleft, ACh exerts its effects on the postsynaptic neuron by binding to muscarinic (M1–M5) and nicotinic receptors. The enzyme AChE in the synaptic cleft breaks down ACh, terminating its action. Overexpression of AChE leads to a decrease in ACh levels, which is associated with the development of AD [48, 49]. **Abbreviations:** ACh: Acetylcholine; ChAT: Choline acetyltransferase; AChE: Acetylcholinesterase; AD: Alzheimer's disease; M1–M5: Muscarinic receptor subtypes 1 to 5.

Despite its historical importance, the cholinergic hypothesis alone cannot fully account for AD complexity. Some early-stage patients demonstrate normal or even elevated acetylcholinesterase (AChE) activity, suggesting that cholinergic deficits may arise later in disease progression and may not be the initiating pathological event [50]. Furthermore, the modest and transient benefits of cholinesterase inhibitors imply that multiple neurotransmitter systems—including dopaminergic, glutamatergic, and serotonergic pathways—also play significant roles in cognitive decline [54]. These findings underscore the need for a broader, multi-system framework when examining the neurochemical basis of AD.

3.9. Oxidative Stress

ROS, reactive nitrogen species (RNS), and other free radical species build up excessively inside cells and cause oxidative stress, which aids in the development and progression of various diseases [50]. In neurodegeneration and AD, oxidative damage products—such as those resulting from the oxidation of lipids, DNA, RNA, or advanced glycation end-products—have been proposed as biomarkers. These molecules can be found in bodily secretions such as blood, serum, plasma, cerebrospinal fluid (CSF), urine, and saliva. It is crucial to determine whether these molecules are present in peripheral circulation and whether they are useful as AD biomarkers. When there is an imbalance in the levels of pro-oxidants and antioxidants, this imbalance can lead to oxidative stress and the destruction of biological molecules linked to AD [55, 56]. Due to its high metabolic activity and high susceptibility to ischemic damage, the brain is particularly vulnerable to oxidative damage. Thus, oxidative stress is crucial to the pathophysiology of AD [57].

Free radicals like ROS and RNS contain one or more unpaired electrons in their outermost shell, making them unstable and highly reactive. ROS and RNS are byproducts of regular cellular metabolism. Numerous pathways and sources can lead to the endogenous production of ROS and RNS. Many enzymes in various subcellular compartments can also produce ROS and RNS, even though the mitochondrial electron transport chain is usually the main source of endogenous reactive species formation [57]. Under both normal and pathological circumstances, mitochondria are the primary source of ROS, and $O_2\bullet^-$ can be produced during cellular respiration. It is important to note that even though these organelles have an innate capacity to salvage ROS, this is insufficient to meet the cell's need to eliminate the quantity of ROS that mitochondria produce. Mitochondrial dysfunction in AD further exacerbates ROS production, as impaired mitochondrial function leads to increased leakage of electrons during oxidative phosphorylation, contributing to the accumulation of ROS [58]. Oxidative damage may arise from excessive ROS generation, a condition known to harm cells and tissues and disrupt signaling pathways [57, 59].

Antioxidant defenses and ROS-generating cellular processes keep ROS in a dynamic equilibrium. When ROS

overwhelms the antioxidant defense mechanisms, oxidative stress occurs. This breakdown in homeostasis results in excessive ROS production or a decrease in defense systems, contributing to cellular dysfunction and damage [60]. The excessive production of ROS and/or a reduction in antioxidant defenses may be linked to the neurodegeneration seen in AD (Fig. 5) [60]. When A β deposition interacts with mitochondria or microglial surface receptors, it can also directly cause an increase in ROS. In the AD brain, oxidative damage to proteins, lipids, mitochondrial DNA, RNA, and other components has been reported [56]. ROS production may be caused by elevated levels of iron and other metals; iron has also been linked to ferroptosis. Additionally, changes in Ca^{2+} influx and the resulting mitochondrial dysfunction are also essential contributors to oxidative damage. Diminished concentrations of distinct lipids have been associated with cognitive impairments in AD, indicating their potential application as biomarkers in AD [56, 60].

3.10. Oxidative Damage and Inflammation in AD

Pathologic indicators of neurodegeneration include oxidative stress and neuroinflammation. ROS are produced in the central nervous system by innate immune cells, and an alternative mechanism for AD-related neuronal damage is the overproduction of oxidants [61]. Neuroinflammation is the general term used to describe the way the central nervous system (CNS) reacts to injury and disease. Within this response, both neural and non-neural cells work in concert to initiate cascades. The complex and diverse structure of the CNS makes it easy to understand how even a small imbalance in any one of its parts could have unintentional effects that hinder rather than help the CNS recover from injury. CNS injury can lead to the production of pro-inflammatory neurotoxic molecules (interleukin-1 (IL-1), IL-6, tumour necrosis factor- α , and transforming growth factor- β), all of which can promote AD pathogenesis [62]. Activated microglia in the early stages of AD facilitate pathologic A β or tau clearance and phagocytosis, which have a positive impact on AD pathologies. However, persistent microglial activation increases the release of inflammatory factors and impairs their capacity to phagocytose and break down neurotoxins. This exacerbates A β accumulation, tau propagation, and neuronal death, ultimately accelerating the progression of AD [63].

Understanding how inflammation and oxidative stress interact in AD is essential to comprehending how AD develops. Oxidative stress and inflammation in AD are closely related, resulting in a vicious cycle that speeds up neurodegeneration [12]. Excess ROS production causes lipid peroxidation, protein modification, and DNA damage, which in turn trigger inflammatory responses. These processes are brought on by a number of factors, including mitochondrial dysfunction, environmental stressors, and glial cell activation [59]. Pro-inflammatory cytokines are released during these inflammatory responses, which are mainly mediated by microglia and astrocytes, and these cytokines can further increase the

production of ROS [64]. The increased ROS levels worsen microglial activation, resulting in persistent inflammation that hinders the glial cells' capacity to eliminate neurotoxic proteins such as tau and A β [59]. This accelerates neuronal damage and cognitive decline in AD by generating a feedback loop of inflammation and oxidative damage [56]. Furthermore, the chronic nature of neuroinflammation in AD is largely due to oxidative stress, which intensifies the activation of particular receptors, such as the Toll-like Receptors (TLRs) on microglia, which sustain the inflammatory response [65]. Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) elicit a response from TLRs, also known as pattern recognition receptors. Several TLRs are expressed in the CNS, primarily in microglia and astrocytes, and these receptors initiate signaling cascades as a defence mechanism through the sustained immune homeostasis-induced synthesis of pro-inflammatory molecules resulting from TLR overactivation [66].

The combined findings of these studies highlight the involvement of oxidative stress and inflammatory markers in AD pathology by showing that they are consistently elevated in AD patients across a range of sample types. A description of these markers, the sample types used for their analysis, and the significant findings connected to each are given in Table 1 [67-78].

3.11. Stages of Ad

The clinical phases of AD can be classified into:

(a) Pre-clinical, also known as the pre-symptomatic stage, which may extend over several years. At the pre-clinical phase, there are currently no clinical signs or symptoms of AD, except for mild memory loss, early pathological alterations in the cortex and hippocampus, or functional impairment in day-to-day activities.

(b) The mild or early stage of AD is defined by symptoms such as trouble focusing and remembering details, disorientation regarding location and time, mood fluctuations, and the onset of depression.

(c) AD in its moderate stage has progressed to regions of the cerebral cortex, resulting in more severe memory loss, inability to recognize friends and family, loss of impulse control, and difficulties with speaking, writing, and reading.

(d) Severe AD, also known as late-phase AD, is characterized by a progressive loss of function and cognition, including the inability to recognize family members, bedridden status, difficulty swallowing and urinating, and ultimately death from these complications. Neuritic plaques and NFTs, a severe accumulation of the disease, spread throughout the entire cortex area [3].




Fig. (5). The molecular targets of free radicals and the resulting oxidative damage. This figure, adapted from [60], depicts how free radicals interact with cellular molecules, such as DNA, proteins, and lipids, leading to oxidative stress and subsequent damage to critical neuronal components [60].

Table 1. Key findings about oxidative stress and inflammation biomarkers in AD patients.

Oxidative Stress Biomarkers	Inflammatory Biomarkers	Sample Type	Findings	References
8-OHdG, 8,12-iso-iPF2 α VI, F2-IsoPs, Protein Carbonyls	IL-1 β , IL-6, IL-8, TNF- α , PGF2 α	CSF	<ul style="list-style-type: none"> The CSF of AD patients had higher levels of IL-6, IL-8, and TNF-α, but IL-1β did not differ from controls [67]. In AD, 8-OHdG was higher in CSF than in controls [68]. In contrast to patients with MCI, A+ patients have higher p-tau levels in the presence of 8,12-iso-iPF2α VI [68]. As the disease progressed, F2-IsoPs rose in CSF in the early stages of AD [68, 69]. There was no significant difference in protein carbonyl levels between AD patients and controls [68]. In patients with A+ MCI, PGF2α is linked to elevated p-tau levels [68]. 	[67-69]
8-OHdG, MDA, F2-IsoPs, Protein carbonyls	IL-6, IL-1 β , IL-2, IL-18, TNF- α , GFAP	Blood	<ul style="list-style-type: none"> Chronic inflammation is suggested by elevated blood levels of IL-1β, IL-2, and IL-18; IL-1β is associated with microglial activation and neurodegeneration, while IL-2 and IL-18 are involved in the inflammatory response [70]. Compared to controls, AD patients' lymphocytes had a higher concentration of 8-OHdG [71]. Elevated plasma MDA levels are observed in AD, although these levels are influenced by external factors such as exercise and smoking [71-73]. F2-IsoPs results on plasma are inconsistent [72]. Higher plasma levels of protein carbonyl are reported in AD [73]. An inflammatory response in AD compared to controls is indicated by higher plasma levels of IL-6 in A+ versus A- individuals [73]. In AD, TNF-α levels in blood are markedly elevated [73]. Compared to healthy elderly individuals, subjects with preclinical AD have significantly higher plasma levels of GFAP [74]. 	[70-74]
MDA and TBARS, Acrolein, F2-IsoPs, 8-OHdG, Protein carbonyls	IL-1, IL-6, TNF- α , TGF- β 1	Brain tissue	<ul style="list-style-type: none"> The brains of AD patients have higher levels of TBARS and MDA [75]. Higher levels of protein carbonyl are found in AD brains [72, 75]. Higher levels of 8-OHdG in the brain are reported in AD [72, 75, 76]. AD is associated with elevated acrolein levels [75]. Increased IL-1 levels in the AD brain are associated with tau phosphorylation, neurofibrillary tangles, and the development of Aβ plaque [77]. Early-stage plaque formation is correlated with elevated IL-6 in the AD brain [77]. In AD, the brain has higher levels of F2-IsoPs [75]. The AD brain has higher levels of TNF-α, which is linked to apoptosis, neuronal toxicity, and cognitive decline [77]. In AD, microglial activation, neuroinflammation, and cognitive decline are all influenced by TGF-β1 deficiency. Cerebrovascular Aβ deposition is correlated with elevated levels seen in the brain and CSF [78]. 	[72, 75-78]

Abbreviations: 8-OHdG: 8-Hydroxy-2'-deoxyguanosine; 8,12-iso-iPF2 α VI: 8,12-iso-Isoprostane F2 α VI; F2-IsoPs: F2-Isoprostanes; MDA: Malondialdehyde; TBARS: Thiobarbituric Acid-Reactive Substances; PGF2 α : Prostaglandin F2 alpha; IL-1 β : Interleukin 1 beta; IL-6: Interleukin 6; IL-8: Interleukin 8; IL-2: Interleukin 2; IL-18: Interleukin 18; TNF- α : Tumor Necrosis Factor alpha; TGF- β 1: Transforming Growth Factor Beta 1; GFAP: Glial Fibrillary Acidic Protein; A β : Amyloid beta; p-tau: Phosphorylated tau; CSF: Cerebrospinal Fluid; AD: Alzheimer's disease; MCI: Mild Cognitive Impairment; A+: Amyloid-positive; A-: Amyloid-negative.

3.12. Familial and Sporadic AD

While familial AD is known as early-onset and is typically inherited in a Mendelian manner, sporadic AD is

typically referred to as late-onset. A very uncommon, early-onset, autosomal-dominant disease, familial AD may occur due to mutations in the presenilin gene and APP,

two genes involved in the metabolism of A β . Sporadic AD is much more common than familial AD, affecting over 15 million people globally [19].

4. CONDITIONS THAT INFLUENCE AD

AD pathogenesis is influenced by multiple factors, including aging, environmental factors, health conditions, and heredity.

4.1. Aging

One of the biggest risk factors for AD is aging, as younger individuals are not frequently affected by this illness. The majority of AD cases develop later in life, typically beyond the age of sixty-five. Aging is a multifaceted, irreversible process that affects many organs and cell systems, where brain volume and mass decrease, synapses are lost, and ventricles enlarge in specific areas, accompanied by NFTs and A β deposits [3]. The likelihood of experiencing cognitive decline is negatively correlated with leading an active physical life. Physical activity is the most widely used approach to investigating how exercise can lessen the negative effects of aging on cognitive performance and is crucial in halting disease progression in older adults through aerobic exercise combined with cognitive stimulation [79].

4.2. Physical and Environmental Factors

It has been documented that sleep instabilities increase levels of A β in the brain fluid of healthy individuals, thereby facilitating neurodegeneration and the emergence of mild cognitive decline [80]. Increased light exposure during the sleep-wake cycle raises insoluble tau levels and impairs memory by inhibiting melatonin, the hormone that regulates sleep-wake cycles. Consequently, irregular sleep patterns have emerged as significant risk factors for AD development and must be appropriately treated with medications that restore physiologically normal sleep cycles [80].

Diet also plays a role in AD pathology. Both deficiencies and excesses of dietary compounds contribute to risk. AD may arise due to deficiencies in antioxidants such as vitamins E and C, folates, and vitamins B6 and B12. Antioxidant vitamins inhibit oxidative stress and A β -induced lipid peroxidation, as well as inflammatory signaling cascades [81].

Furthermore, smoking may raise the risk of AD by generating free radicals, elevating oxidative stress, and stimulating the immune system's pro-inflammatory response through phagocyte activation. These effects can lead to cerebrovascular diseases, which in turn elevate AD risk [81].

4.3. Health Conditions

AD and hypertension are interrelated. The relationship is driven by cerebrovascular disease, as hypertension alters vascular walls, causing cerebral ischemia, which leads to the accumulation of A β and the eventual development of AD [80]. Obesity is also widely recognized to increase the risk of type II diabetes, cardiovascular

disease, and neurodegenerative illnesses such as AD. Chronic obesity-related hyperglycemia increases A β accumulation, oxidative stress, and neuroinflammation via the release of pro-inflammatory cytokines, ultimately contributing to cognitive impairment [3].

Additionally, research has shown a connection between depression and elevated A β deposition in patients [81]. Neurotransmitters such as serotonin and dopamine play important roles in AD pathophysiology as well as depression. These neurotransmitters may be crucial in the progression of AD stemming from depression. While dopamine loss damages memory, dopamine release improves cognitive function. Depression is characterized by low serotonin levels and reduced dopamine production [82].

4.4. Genetic Risk Factors

AD can be divided into groups based on when the first symptoms manifest. About 4-6% of AD cases are early-onset, affecting individuals below 65 years, whereas late-onset AD affects those above 65 years [83]. Late-onset AD is primarily associated with a polymorphism in the APOE gene, specifically the presence of the ϵ 4 allele, whereas early-onset AD typically results from fully penetrant mutations in PSEN1, PSEN2, and APP [83].

The APP gene, located on chromosome 21q21, has been linked to more than 30 dominant mutations, accounting for 15% of early-onset autosomal dominant AD cases [61]. When APP is cleaved, many A β peptides are produced; the most prevalent is A β 1-42, which is primarily found in senile plaques. The more soluble A β 1-40 is associated with cerebral microvessels and may appear later in the disease. Depending on the mutation type, soluble peptide oligomers may also play a role, providing a genetic basis for variations in familial AD pathophysiology [84].

ApoE is a glycoprotein involved in lipid metabolism and is highly expressed in brain and liver astrocytes, as well as certain microglia. It is encoded by the APOE gene on chromosome 19. Three ApoE alleles (ϵ 2, ϵ 3, and ϵ 4) produce the ApoE2, ApoE3, and ApoE4 isoforms, respectively [3, 84]. The ApoE ϵ 4 allele poses a substantial risk for both early-onset and late-onset AD, whereas ApoE ϵ 2 has a protective effect, and ApoE ϵ 3 is neutral. ApoE ϵ 4 promotes senile plaque formation of A β and contributes to cerebral amyloid angiopathy (CAA), a marker associated with AD [3].

5. THERAPEUTIC STRATEGIES IN AD

The goal of therapeutic approaches for AD is to reduce symptoms and delay the disease's progression.

5.1. Symptomatic Treatment of AD

Among the most established and time-tested theories regarding the pathophysiology of AD is the cholinergic hypothesis. ACh is an excitatory neurotransmitter involved in cognitive behaviours and is regulated by the cholinergic nerve network. According to this theory, the pathophysiology of AD is accompanied by the loss of cholinergic functions in different brain regions, including the hippocampus.

ampus and cortex [85]. Inhibiting AChE is one method to raise cholinergic levels, which is thought to improve brain and neural cell function. Acetylcholinesterase inhibitors (AChEIs) block the breakdown of ACh in synapses, resulting in its sustained accumulation and continued cholinergic receptor activation [3].

Cholinesterase inhibitors and NMDA-receptor antagonists are part of currently approved therapies; however, while their combination can provide more than momentary symptom relief and may extend a patient's retention of cognitive function for several months, their impact on long-term disease progression remains limited [86]. The Food and Drug Administration (FDA) approved tacrine as the first AChEI for AD treatment. This drug increases ACh in muscarinic neurons. However, due to a high frequency of side effects, including hepatotoxicity, documented in multiple trials, it was withdrawn from the market. Currently, the FDA has approved rivastigmine, donepezil, and galantamine as AChE inhibitors, as well as the NMDA antagonist memantine [3]. The most frequent side effects of these medications are gastrointestinal—such as nausea, vomiting, diarrhoea, and anorexia—although most patients tolerate them. Memantine, a non-competitive NMDA antagonist, reduces glutamate-induced excitatory neurotoxicity and has demonstrated modest efficacy and safety in moderate to severe AD. When combined with AChE inhibitors, memantine provides additional benefits compared with monotherapy [87].

5.2. Donepezil

Donepezil, a piperidine AChE inhibitor, is commonly prescribed to treat AD [88]. By reversibly binding to AChE and inhibiting ACh hydrolysis, donepezil increases ACh levels at synapses. The medication has mild and temporary cholinergic side effects related to the nervous and gastrointestinal systems, but is generally well tolerated. Donepezil improves symptoms of AD—such as behaviour and cognition—without slowing disease progression [3].

Inhibition of glycogen synthase kinase-3 β (GSK-3 β) strengthens synaptic and cognitive functions. Curcumin, often delivered using nanocarriers to improve effectiveness, possesses neuroprotective properties in various CNS disease models and can cross the blood-brain barrier (BBB). Combined treatment with donepezil and curcumin has shown synergistic effects in AD by modulating the GSK-3 β pathway, which otherwise promotes A β accumulation and tau phosphorylation, leading to memory impairment [89].

5.3. Galantamine

Galantamine is a phytochemical alkaloid capable of crossing the BBB and increasing central cholinergic tone. It also reversibly inhibits AChE activity [90]. This tertiary isoquinoline alkaloid acts selectively in two ways: it binds allosterically to the α -subunit of $\alpha 7$ -nAChR to activate it, and it competitively inhibits AChE [3].

Galantamine is considered an initial therapy for mild to moderate AD; however, due to its limited efficacy and potential side effects with continuous use, combining GAL

with other compounds has been suggested. One such compound is fisetin, found in fruits and vegetables, which reversibly and effectively inhibits both butyrylcholinesterase and AChE *in vitro* [91].

5.4. Rivastigmine

Rivastigmine, a phenyl-carbamate derivative, functions as a dual inhibitor of butyrylcholinesterase (BuChE) and AChE. BuChE is not inhibited by galantamine or donepezil. Because BuChE levels rise in the hippocampus and temporal cortex of AD patients as the disease progresses, while AChE activity decreases, rivastigmine's ability to inhibit both enzymes involved in ACh hydrolysis may have important clinical implications. Dual inhibition increases the brain's ACh levels [92]. Adverse effects—including nausea, vomiting, dyspepsia, asthenia, anorexia, and weight loss—are associated with oral rivastigmine administration. Although tolerable, these side effects are a common reason for discontinuation [3, 92].

5.5. Targeting A β

The amyloid cascade hypothesis assumes that the primary cause of the neurodegenerative process of AD is the accumulation of A β peptide and its subsequent aggregation and deposition in the form of A β plaques [87]. Approaches to target A β in AD include modulating β -secretase activity, using γ -secretase modulators, preventing A β aggregation, or clearing A β to reduce its production [93].

5.6. β -Secretase Inhibitor

Inhibitors of β -secretase primarily lower the amount of A β produced [93]. It is known that the production of A β 42 is restricted by the inhibition of BACE [87, 93]. Although many BACE1 inhibitors have recently been developed, only five—verubecestat, lanabecestat, atabecestat, umibecestat, and elenbecestat—have advanced to Phase III clinical trials. All five medications effectively lowered A β levels in the CSF of AD patients. However, due to the lack of cognitive or functional benefit, these compounds were discontinued, and in some cases, a decline in cognitive function was observed [87].

5.7. Gamma (γ)-Secretase Inhibitor

A γ -secretase inhibitor cleaves multiple substrates, including amyloid. The γ -secretase complex plays a physiological role in sustaining neuronal development by contributing to the differentiation of neuronal cells and preserving a reservoir of neural progenitor cells [94]. Semagacestat, a non-selective small-molecule γ -secretase inhibitor, decreases A β deposition through the same mode of action as β -secretase inhibitors [93, 94]. Apart from the risks of skin cancer and weight loss, Phase III clinical trials for semagacestat were terminated early because patients with AD began to exhibit marked cognitive decline. Another γ -secretase inhibitor, avagacestat, also failed to demonstrate promising outcomes in AD [86].

5.8. Inhibiting the Formation of A β Aggregation

After amyloid monomers group together to form

hazardous oligomers, β -sheets are formed, eventually accumulating as plaques in the extracellular matrix [94]. Several medicinal compounds have been developed to specifically target and prevent amyloid aggregation. Early clinical trials showed promising results for two drugs, tramiprosate and colostrinin. Tramiprosate, an amino acid naturally found in seaweed, modulates GABA receptors to exert neuroprotective effects. By preventing glycosaminoglycan binding to $A\beta$, it inhibits $A\beta$ aggregation and β -sheet formation. However, its Phase III trials did not yield the anticipated positive outcomes. Colostrinin, a proline-rich polypeptide extracted from ovine colostrum, has been shown to prevent $A\beta$ aggregation by influencing the innate immune system, but it also did not produce encouraging results in Phase II trials [86, 94].

5.9. Immune-based Therapies: Elimination or Clearance of Amyloid Clusters

Since $A\beta$ accumulation and aggregation are considered the primary cause of the neurodegenerative process in AD, targeting $A\beta$ clearance with specific anti- $A\beta$ antibodies is a logical strategy. Immunotherapy directed at $A\beta$ is one of the most effective methods to slow AD progression. This therapy can be categorized into active and passive immunotherapies [87].

5.9.1. Active Immunotherapy (Vaccine)

Active immunotherapy stimulates the body's immune system to generate antibodies against $A\beta$ by injecting the protein or its fragments [87]. The first anti- $A\beta$ vaccine (AN1792) demonstrated that $A\beta$ plaques could be effectively eliminated by active immunotherapy, with effects lasting up to 14 years. However, meningoencephalitis (ME) occurred in approximately 6% of AD patients receiving AN1792 in the Phase IIa trial, leading to its termination [95]. This adverse effect was attributed to a T-cell-mediated immune response. Despite this, AN-1792 showed positive outcomes in clearing amyloid plaques from the brain [87-95].

To address these issues, a novel vaccine, ACC-001, was developed to accelerate $A\beta$ plaque removal while avoiding harmful T-cell responses. Phase II clinical trials of ACC-001 in individuals with mild to moderate AD demonstrated acceptable safety regardless of the inclusion of the QS-21 adjuvant. Furthermore, ACC-001 + QS-21 generated higher anti- $A\beta$ antibody levels compared to the group without QS-21 [93]. ACC-001, which uses a carrier protein, an active saponin adjuvant (QS-21), and a short $A\beta$ fragment, is currently in a long-term Phase II trial with promising results [95].

5.9.2. Passive Immunotherapy

Passive immunotherapy involves administering monoclonal antibodies or immunoglobulins [86]. Six antibodies—BAN2401, solanezumab, crenezumab, gantenerumab, aducanumab, and bapineuzumab—have entered Phase III clinical trials. Although most monoclonal antibodies have shown the ability to reduce CSF

biomarker levels and $A\beta$ plaques, only a few have demonstrated clinical efficacy [87]. Monoclonal antibodies targeting $A\beta$ in randomized clinical trials have been associated with MRI-detected abnormalities known as amyloid-related imaging abnormalities (ARIA) [96]. In clinical trials, both lecanemab and donanemab slowed AD-associated cognitive decline. Lecanemab, approved in the United States, is specific for early AD with confirmed brain amyloid pathology [97]. Lecanemab, a high-affinity monoclonal antibody for large, soluble $A\beta$ protofibrils, demonstrated robust efficacy and manageable risk in Phase II trials and is currently in Phase III [98]. Approved by the FDA in January 2023, it reduces $A\beta$ accumulation and slows cognitive decline, with significant improvements across multiple clinical measures. Common adverse effects include headache, infusion reactions, and ARIA [99]. Similarly, donanemab reduced brain $A\beta$ plaques and significantly slowed disease progression in early symptomatic AD. Participants treated with donanemab had a reduced risk of progressing to the next disease stage. Adverse effects included ARIA and some infusion-related reactions [100].

5.10. Targeting Tau

The two mechanisms responsible for both increased neuronal loss and the development of NFTs are tau deposition and phosphorylation [86].

5.10.1. GSK-3 β Inhibitor

It is possible to regulate increased tau phosphorylation by blocking the GSK-3 enzyme [86]. Evidence supports the use of GSK-3 β inhibitors, such as lithium, in AD therapeutics by demonstrating that GSK-3 β overactivity mediates tau hyperphosphorylation [94]. Lithium inhibits GSK-3 and also affects glial cell function, glucose metabolism, and cell signaling and proliferation. Lithium can prevent tau hyperphosphorylation and amyloid production, and certain case reports and case-control studies have demonstrated that lithium can lessen AD symptoms. However, prolonged use of clinically available lithium is associated with serious adverse effects [93].

5.10.2. Inhibition of Tau Aggregation

In AD, the growth and accumulation of tau aggregates are linked to neuronal loss and functional impairment [87]. Hydromethanesulfonate and methylthioninium chloride are examples of tau aggregation inhibitors capable of reducing tau accumulation [93]. The ability of methylthioninium, a member of the diaminophenothiazine class of compounds, to inhibit tau aggregation has been investigated [94]. However, in a Phase II study, methylthioninium chloride did not demonstrate clinical benefit in AD. Additionally, a Phase II hydromethylthionine trial in mild-to-moderate AD was abruptly stopped for administrative reasons [93].

5.11. Drugs Targeting Neuroinflammation

Numerous NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) have been investigated. One of the most widely used NSAIDs is ibuprofen, and studies have shown that it

may improve cognitive impairment [101]. It has been observed that administering oral ibuprofen to mice that overexpress human APP lowers total brain A β levels, plaque burden, and neuroinflammation [102]. Acetaminophen (paracetamol) is another commonly used analgesic and antipyretic that has been demonstrated in mice to exert neuroprotective, antioxidant, and anti-inflammatory effects. It also appears to improve cognitive impairment by blocking the mitochondrial permeability transition (MPT) pore and the subsequent apoptotic pathway [101].

However, there is a risk of adverse effects with both acetaminophen and ibuprofen, especially when they are used frequently or in high doses [103]. In particular, in the elderly population, long-term ibuprofen use has been linked to gastrointestinal problems such as bleeding and ulcers [104]. Furthermore, some research indicates that long-term NSAID use may not improve cognition and may even worsen cognitive decline due to adverse side effects [104, 105]. Likewise, although acetaminophen is generally regarded as safe when taken as prescribed, prolonged or excessive use can cause hepatotoxicity and has been associated in certain observational studies with a higher risk of cognitive impairment. Therefore, even though these drugs might have neuroprotective effects in some situations, their possible side effects make them risky to use, especially in individuals who are at risk of AD [106, 107].

5.12. Role of Functional Food-based Strategies in the Treatment of AD

There is currently no effective treatment for AD. This calls for the identification of viable and more effective treatments that specifically target pathological features of AD. AD remains progressive and incurable despite massive efforts to find a cure. Studies indicate that consuming antioxidant-rich foods may lower the risk of AD by reducing oxidative stress and inflammation, both of which play critical roles in its onset and progression [10]. Functional foods, rich in bioactive compounds, have gained attention for their potential to modulate the oxidoinflammatory balance in AD (Fig. 6) [2, 10]. Preventing the excessive production of ROS and modulating inflammatory pathways may therefore represent a promising strategy to counteract the onset and progression of AD, thus offering a potentially useful approach for AD management [2]. The current review provides an overview of the medicinal potential of various bioactive compounds present in functional foods in this respect.

5.12.1. Quercetin

This naturally occurring flavonoid, quercetin, is present in many foods, such as tea, apples, berries,

grapes, onions, and other fruits and vegetables [108]. The complex neuroprotective properties of quercetin have attracted significant interest. Its capacity to alter oxidative stress, inflammation, and other pathological pathways linked to AD is what gives it therapeutic potential [109].

Quercetin has strong antioxidant properties that improve endogenous antioxidant defenses and efficiently scavenge ROS. It induces the upregulation of heme oxygenase-1 (HO-1), an essential enzyme in cellular defense against oxidative damage, by activating the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) pathway [109, 110]. In addition to lowering oxidative stress, this activation also has anti-inflammatory effects by blocking the Nuclear Factor-Kappa B (NF- κ B) signaling pathway, which reduces the synthesis of pro-inflammatory cytokines like TNF- α and IL-1 β [111]. Moreover, quercetin has been demonstrated to alter the activity of key enzymes that regulate neurotransmitters, including BuChE and AChE, which may improve cognitive function by boosting cholinergic transmission [112].

Furthermore, quercetin improves mitochondrial function and energy metabolism by activating the AMP-Activated Protein Kinase (AMPK) pathway [113]. In animal models of AD, preclinical research has shown quercetin's effectiveness in reducing neuropathological alterations and improving cognitive deficits [114]. For example, administering quercetin to transgenic mice improved memory function, decreased neuroinflammation, and reduced A β plaque formation. In triple-transgenic Alzheimer's disease (3xTg-AD) mice, performance on cognitive tests such as the elevated plus maze test showed that quercetin treatment significantly improved spatial learning and memory. Additionally, it significantly decreased neuroinflammatory markers in the hippocampus and amygdala, such as microgliosis and astrogliosis, as shown by a decrease in glial fibrillary acidic protein (GFAP) immunoreactivity, suggesting suppressed astrocyte activation. Furthermore, quercetin treatment resulted in a notable reduction in extracellular β -amyloidosis in these brain areas, as evidenced by decreased levels of A β 1-40 and A β 1-42 peptides, as well as a decrease in BACE1-mediated cleavage of APP, a crucial stage in the development of A β plaque [115-117].

Frequent ingestion of these foods may have neuroprotective effects and help delay or prevent the onset of AD. However, because of its rapid metabolism and poor absorption, quercetin has relatively low bioavailability. To optimize its therapeutic efficacy, methods to increase its bioavailability—such as the use of quercetin glycosides or nanoparticle formulations—are being investigated [118]. Quercetin is a promising option for AD treatment because of its ability to regulate inflammation, oxidative stress, and other pathological processes. Nevertheless, more clinical research is necessary to confirm its effectiveness and determine optimal dosage regimens.




Fig. (6). Neuroprotective mechanisms of functional foods. The diagram depicts how functional foods support brain health through four main mechanisms: antioxidant/metabolic support, anti-inflammatory effects, anti-amyloid/protein regulation, and cholinergic support [2, 10].

Abbreviations: ROS: Reactive oxygen species; Nrf2: Nuclear factor erythroid 2 related factor 2; AMPK: AMP-activated protein kinase; Aβ: Amyloid-beta; AChE: Acetylcholinesterase; BuChE: Butyrylcholinesterase; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; TNF-α: Tumor necrosis factor alpha; IL-1β: Interleukin-1 beta.

5.12.2. Curcumin

The rhizome of *Curcuma longa*, or turmeric, contains a polyphenolic compound called curcumin, which has attracted significant interest due to its potential neuroprotective benefits in AD. It is a promising option in the treatment of AD due to its diverse mechanisms of action, which include anti-inflammatory, anti-amyloid, and antioxidant properties [116, 119].

Oxidative stress is one of the defining characteristics of AD, contributing to both neuronal damage and cognitive decline [109]. It has been demonstrated that curcumin activates the Nrf2 pathway, which results in the upregulation of HO-1, an enzyme essential for protecting cells from oxidative damage. This activation reduces oxidative stress-induced neuronal damage by boosting neurons' antioxidant capacity [120]. Along with its

antioxidant effects, curcumin has strong anti-inflammatory properties. It prevents the transcription factor NF-κB, which controls the production of pro-inflammatory cytokines, from becoming activated. By inhibiting NF-κB activation, curcumin lowers the synthesis of inflammatory mediators like ILs and TNF-α, which reduces the neuroinflammation linked to AD [121].

Curcumin also prevents Aβ peptides from pathologically aggregating. It has been shown to inhibit Aβ aggregation and encourage the disintegration of pre-existing fibrils, thereby lessening Aβ-induced neurotoxicity [122]. Further adding to curcumin's neuroprotective profile is its capacity to chelate metal ions, such as iron and copper, which are linked to oxidative stress and Aβ aggregation [123].

Curcumin's poor bioavailability is the main reason why

clinical studies examining its effectiveness in AD have produced conflicting findings. However, developments in formulation techniques, such as the creation of phospholipid complexes and curcumin nanoparticles, have demonstrated promise in improving the drug's bioavailability and therapeutic effectiveness [124, 125]. Daily consumption of Theracurmin, a bioavailable curcumin formulation, for 18 months considerably enhanced memory and attention in middle-aged and older adults with mild cognitive impairment, according to a recent randomized, double-blind, placebo-controlled study. The Buschke Selective Reminding Test and Trail Making Test revealed cognitive improvements, while PET imaging revealed reduced A β and tau buildup in the amygdala and hypothalamus [126]. These effects are attributed to curcumin's anti-inflammatory, antioxidant, and anti-amyloid properties, which are further strengthened by nanoparticle technology's increased bioavailability [126, 127].

According to the study, long-term supplementation with bioavailable curcumin may slow cognitive decline in at-risk populations and provide neuroprotective benefits, despite its small sample size [126]. Although curcumin's direct brain penetration remains limited, these mood and cognitive benefits are likely mediated by its systemic actions, underscoring its potential as a low-cost, well-tolerated treatment to slow age-related cognitive decline [128].

5.12.3. Carotenoids

Carotenoids are vibrant pigments with significant antioxidant and anti-inflammatory properties that are present in fruits, vegetables, and seaweeds. Of all the known carotenoids, the most well-characterized and researched for their roles in various diseases and conditions are α -carotene, β -carotene, lutein, zeaxanthin, lycopene, and β -cryptoxanthin. When comparing AD patients to healthy controls, low blood carotenoid levels are commonplace, and plant-based diets are thought to be neuroprotective. Improved cognitive function is linked to increased levels of β -cryptoxanthin, an oxidized carotenoid, in the blood. Additionally, given that circulating α - and β -carotene levels are markedly lower in AD, there is evidence that they could function as non-invasive disease biomarkers [2].

An observational study found that adults with high serum levels of lutein and zeaxanthin or lycopene had a lower risk of AD mortality [129]. It has been demonstrated that these substances neutralize ROS, reducing oxidative damage to neural cells. By modifying inflammatory pathways, such as the inhibition of NF- κ B activation, which is linked to the neuroinflammation associated with AD, carotenoids also demonstrate anti-inflammatory properties [130]. Carotenoids may also have neuroprotective effects by influencing other important pathways in AD, such as the regulation of tau phosphorylation and A β aggregation [131].

Therefore, including fruits and vegetables high in carotenoid content in the diet can offer a multimodal

approach to managing AD, addressing inflammation and oxidative stress while also possibly slowing the course of the disease [130, 131].

5.12.4. Vitamins

Recent years have seen a thorough review of the role vitamins play in AD and cognitive disorders. They play a role in protecting the body against oxidative stress and damage. While vitamin E's role in AD pathogenesis and progression is the subject of much recent debate, deficiencies in vitamins A, D, K, and E are implicated in AD and its cognitive decline [2]. Emerging studies demonstrate how some vitamins may be able to control inflammation and oxidative stress in the development of AD. Due to its antioxidant qualities, vitamin E has been researched for its potential to shield neuronal membranes from oxidative damage [132].

High-dose vitamin E supplementation (2000 IU/day) has been shown in clinical trials, including the TEAM-AD study, to slow the functional decline of patients with mild-to-moderate AD. Despite a compelling case for vitamin E's effectiveness as an AD intervention, the available clinical data are still inconclusive [133, 134].

Additionally, vitamin D has been linked to cognitive function. A randomized, double-blind, placebo-controlled trial investigated the effects of daily oral vitamin D₃ supplementation (800 IU) over 12 months on cognitive function and A β -related biomarkers in older adults diagnosed with AD. The study involved 210 participants, who were randomly assigned to receive either vitamin D₃ or a placebo. The results demonstrated significant improvements in cognitive performance. Additionally, plasma levels of A β ₄₂, APP, and BACE1 were significantly reduced in the intervention group compared to the placebo group. These findings suggest that vitamin D₃ supplementation may positively influence cognitive function and modulate A β -related biomarkers in Alzheimer's patients. The authors concluded that larger-scale, longer-term randomized trials are necessary to further explore the potential therapeutic role of vitamin D in AD management [135, 136].

The metabolism of homocysteine depends on B vitamins, especially B6, B9 (folic acid), and B12. Elevated homocysteine levels are associated with a higher risk of AD [137]. According to the VITACOG trial, taking B vitamins significantly decreased the rate of brain atrophy in people with mild cognitive impairment, particularly in those with higher baseline homocysteine levels [138]. These results call for more research into the therapeutic potential of targeted vitamin interventions since they may have neuroprotective effects and interfere with the oxidative and inflammatory pathways implicated in AD.

5.12.5. Resveratrol

A polyphenol known as resveratrol is found in a variety of plants, including grapes, peanuts, cranberries, blueberries, and blackberries. It was shown in a study that grape powder containing resveratrol prevented changes in

cerebral metabolism in people with mild cognitive impairment and was associated with enhanced working memory and attention; consequently, resveratrol is an antioxidant that may be useful in the treatment of AD [129]. According to preclinical research, resveratrol can lessen neuronal damage by reducing oxidative stress by activating the brain's antioxidant systems, including glutathione and superoxide dismutase 2 (SOD2) [139]. Furthermore, by preventing the synthesis of proinflammatory factors and reducing the activation of astrocytes and microglia, which are linked to AD pathology, resveratrol demonstrates anti-inflammatory properties [140].

The safety and effectiveness of resveratrol in AD patients have been investigated in clinical trials. According to a randomized, double-blind, placebo-controlled study, resveratrol is safe, well-tolerated, and may modify the course of some AD biomarkers [141]. Additionally, resveratrol supplementation preserved hippocampal volume and improved functional connectivity in people at risk for dementia, according to a proof-of-concept study [142]. Although more research is required to fully elucidate its clinical efficacy, these findings imply that resveratrol may offer therapeutic benefits in modulating oxidative stress and inflammation in AD.

5.12.6. Ebselen

Despite the fact that ebselen does not naturally occur in food, its selenium component can be acquired through selenium-rich foods. Brazil nuts—one of the best natural sources of selenium—as well as meats (such as beef and poultry), seafood (such as tuna and sardines), eggs, and whole grains are examples of functional foods high in selenium [143]. Numerous antioxidants, including ebselen, have been studied for their capacity to penetrate the BBB and function as neuroprotectants when given singly, in combination, or conjugated with other substances. The potential glutathione peroxidase-like effects of the selenium-containing compound ebselen, involved in the scavenging of free radicals, have also been evaluated. Selenium is a crucial trace element that, *via* oxidative stress resistance, keeps the brain's antioxidant activity intact [10]. Its free radical scavenging activity may be able to help treat AD. Using a combination of antioxidant compounds rather than just one may improve the drug therapy's overall antioxidant ability, increase the antioxidants' bioavailability in different cellular locations, and enhance their functionality [10, 129].

Furthermore, ebselen exhibits anti-inflammatory properties by regulating microglial activation and preventing the synthesis of pro-inflammatory cytokines, which may lessen neuroinflammation linked to the advancement of AD [144]. According to preclinical research, ebselen can inhibit cerebral AChE activity, which may help maintain cholinergic neurotransmission, a process frequently impaired in AD [145, 146]. Although ebselen's effectiveness in treating conditions like stroke and bipolar disorder has been the main focus of clinical trials, its neuroprotective mechanisms present a promising avenue for research on AD [147].

5.12.7. Melatonin

A variety of functional foods serve as dietary sources of melatonin, with tomatoes, olives, barley, rice, and walnuts being among the most abundant sources [148]. Including these foods in the diet may help maintain endogenous melatonin levels, which may have neuroprotective effects and modulate oxido-inflammatory pathways linked to AD [149]. The pineal gland secretes the peptide hormone melatonin, which plays a role in controlling the circadian rhythm. It was discovered that the plasma and CSF of people with AD had decreased levels of melatonin at night [129]. Furthermore, the likelihood of early institutionalization is elevated in people with AD who have sleep disorders. Consequently, melatonin has garnered more attention as a potential treatment for AD because circadian rhythm disruptions might influence the development of oxidative stress in AD. Melatonin supplements may help regulate the circadian rhythm [129]. Melatonin's anti-inflammatory and antioxidant effects in microglial cell lines may indicate a key neuroprotective mechanism for the hormone's action against p-tau neurotoxicity [150]. Melatonin has been shown in preclinical research to have neuroprotective effects by lowering the synthesis of tau and A β [151]. In patients with mild to moderate AD, a randomized controlled trial showed that prolonged-release melatonin stabilized cognitive function and enhanced sleep quality over 6 months [152].

5.12.8. Silibinin

Silibinin, an antioxidant derived from *Silybum marianum*, is mostly present in milk thistle seeds and is not frequently found in everyday foods. On the other hand, silibinin can be found in herbal teas and milk thistle supplements. Furthermore, attempts have been made to include silibinin in functional foods; for instance, the creation of fermented milk products that contain silibinin seeks to improve its therapeutic potential and bioavailability [153, 154]. A study discovered that silibinin is a multi-target inhibitor of the enzyme AChE and A β peptide accumulation, pointing to a possible AD remedy [150]. Silibinin can reduce cognitive dysfunction and prevent A β aggregation, according to preclinical research [155]. Studies using APP/PS1 transgenic mice, for example, demonstrated that silibinin treatment altered the processing of amyloid precursor protein and decreased oxidative stress in the brain, improving cognitive function [156]. The strong anti-inflammatory and antioxidant properties of silibinin are thought to be responsible for its neuroprotective effects. It reduces oxidative damage by scavenging ROS and inhibits the release of pro-inflammatory cytokines like TNF- α and IL-1 β , as well as the activation of microglia. These activities support the preservation of the oxido-inflammatory balance, which is essential for halting AD progression and neuronal damage [155, 157]. Despite limited clinical research on silibinin's effectiveness in AD patients, preclinical data suggest that it may be a neuroprotective agent. To completely clarify its therapeutic advantages and the best ways to deliver it, more clinical research is necessary.

5.12.9. Chlorogenic Acid

It has been demonstrated that chlorogenic acid, a phenolic acid extracted from fruits and vegetables, has neuroprotective properties in relation to AD [158, 159]. Its medicinal effect is mediated at the biochemical level by pro-inflammatory cytokine modulation and inhibition, as well as its effectiveness in scavenging free radicals, all of which aid in managing the course of neurological conditions [160]. In animal models of AD, preclinical studies have shown that chlorogenic acid is effective in lowering A β deposition, reducing neuroinflammation, and improving cognitive functions [161]. For example, an 8-week intervention that combined chlorogenic acid supplementation with aerobic exercise activated the Sirtuin 1 (SIRT1) and Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha (PGC-1 α) signaling pathway, which reduced oxidative stress and improved cognitive performance in mice [162]. Additionally, chlorogenic acid has been shown to cross the BBB, allowing it to exert its neuroprotective effects directly within the central nervous system [163]. Although these results are encouraging, more clinical trials are required to fully elucidate chlorogenic acid's therapeutic potential and establish standardized dosing regimens for successful intervention in human populations [161, 164].

5.12.10. Mediterranean Diet

The potential benefits of the Mediterranean diet (MeDi), which is defined by a moderate intake of wine and fish and a high intake of fruits, vegetables, whole grains, legumes, nuts, and olive oil, have been thoroughly investigated [165]. Its potent anti-inflammatory and antioxidant properties are thought to support cognitive function and neuroprotection. Antioxidants such as vitamins C and E, carotenoids, and polyphenols, which are abundant in the MeDi, help scavenge free radicals and reduce oxidative damage in the brain [166]. Furthermore, anti-inflammatory components of the diet, including monounsaturated fats from olive oil and omega-3 fatty acids from fish, have been linked to decreased levels of inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP), collectively contributing to the diet's neuroprotective effects [166, 167].

Clinical data supports the MeDi's cognitive benefits. In comparison to a low-fat control diet, individuals adhering to a MeDi supplemented with extra virgin olive oil or mixed nuts demonstrated significant improvements in cognitive performance in the PREDIMED-NAVARRA randomized trial, which evaluated 522 participants at high vascular risk. In particular, the Mini-Mental State Examination (MMSE) and Clock Drawing Test (CDT) mean scores were higher in the MeDi groups, suggesting improved global cognitive function [168, 169]. The impact of the MeDi on age-related cognitive decline was further examined in another randomized clinical trial involving 447 cognitively healthy volunteers at high cardiovascular risk who were assigned either a control diet or a MeDi supplemented with mixed nuts or extra virgin olive oil. Compared with the control group, participants in the MeDi

groups showed improved cognitive performance after a median follow-up of 4.1 years, especially in tests of memory and executive function [168, 169].

Taken together, these findings suggest that the Mediterranean diet may help prevent and manage AD due to its anti-inflammatory and antioxidant properties. Incorporating MeDi principles into one's lifestyle may therefore serve as a practical strategy to reduce the risk of neurodegenerative diseases and promote long-term cognitive health [166].

5.12.11. Precision Medicine

Alzheimer's disease (AD) exhibits significant variability in its clinical presentation, disease course, susceptibility to risk factors, and treatment response. To optimize outcomes, this heterogeneity underscores the need for a precision medicine approach that tailors interventions to each patient's biological and clinical characteristics [170]. Clinically, AD manifests with diverse cognitive impairments extending beyond typical episodic memory loss. Some patients present with early deficits in language, executive function, or visuospatial processing, leading to diagnoses such as logopenic variant primary progressive aphasia or posterior cortical atrophy [171]. Phenotypic variation is influenced by factors including sex, genetic background, and age at onset [172]. For example, early-onset AD (EOAD) progresses more rapidly than late-onset AD (LOAD) and often presents with atypical symptoms. A comparative neuropsychological study reported that individuals with EOAD exhibited a more aggressive trajectory of cognitive decline, with disproportionate impairments in non-memory domains such as attention, working memory, and visuospatial skills [173].

Disease progression in AD is similarly variable. While some individuals experience gradual decline over many years, others deteriorate more rapidly. Lifestyle factors, such as poor dietary habits and physical inactivity, as well as chronic comorbid conditions—including diabetes and cardiovascular disease—can significantly influence the rate of cognitive decline [174]. Genetic factors also play a critical role; in particular, the apolipoprotein E ϵ 4 (APOE ϵ 4) allele is associated with earlier onset and accelerated progression of AD [175]. The APOE ϵ 4 allele, which contributes to cholesterol dysregulation, is the strongest known genetic risk factor for sporadic AD, though risk magnitude varies across ancestries and clinical contexts. Currently, a limited number of diagnostic assays are available to assess APOE genotype and amyloid ratios [176]. Notably, the ϵ 4 allele increases AD risk, whereas the ϵ 2 allele confers protective effects. Individuals carrying two ϵ 4 alleles have an even greater risk compared with heterozygous carriers [177].

Precision medicine refers to individualized healthcare strategies that customize therapies based on a patient's unique biological profile, with the aim of improving therapeutic efficacy, enhancing preventive strategies, and minimizing adverse effects by moving beyond a "one-size-fits-all" model [178]. A prominent example is donanemab, a monoclonal antibody targeting a modified form of

deposited amyloid- β (A β). In a phase 2 trial involving patients with early symptomatic AD confirmed by tau and amyloid PET biomarkers, donanemab significantly slowed cognitive and functional decline over 76 weeks compared with placebo [179]. These findings illustrate the potential of biomarker-guided treatment approaches in AD, in which therapeutic selection is informed by precise pathological signatures to maximize benefit.

In addition to monoclonal antibodies, several natural compounds have been investigated for their potential integration into precision medicine strategies for AD. Phytochemicals such as curcumin and quercetin possess neuroprotective properties that may complement individualized treatment plans [129]. Curcumin acts through multiple mechanisms relevant to AD pathology, including A β binding, anti-inflammatory activity, and antioxidant effects [180]. However, its limited bioavailability has constrained clinical application. To address this, nanotechnology-based delivery systems have been developed to enhance solubility and brain penetration. For example, curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide demonstrated improved cellular uptake and blood-brain barrier (BBB) permeability *in vitro* and *in vivo*, resulting in reduced A β production in AD mouse models [181, 182].

Quercetin has likewise been explored for its therapeutic potential in AD. It reduces A β aggregation and promotes its clearance through autophagic pathways, while also exerting potent antioxidant and anti-inflammatory effects. Preclinical studies show that quercetin can attenuate neurodegeneration and facilitate removal of A β aggregates, either alone or in combination with other flavonoids such as wogonin and silibinin [183]. These findings suggest that quercetin may serve as a targeted intervention for individuals with amyloid pathology or heightened oxidative stress within a precision medicine framework.

Although natural compounds such as curcumin and quercetin demonstrate promise, further clinical research is essential to fully define their safety, efficacy, and optimal delivery methods in the context of personalized AD treatment.

5.13. Clinical Evidence for Functional Dietary Interventions in AD

Trials investigating whether dietary or supplemental plant antioxidants can slow cognitive deterioration are increasing. For example, in a 24-week randomized controlled trial (RCT), healthy older adults taking a daily supplement of 50 mg of onion containing quercetin showed significant improvements in their MMSE scores compared to placebo [184]. In another small pilot trial of older adults at risk of cognitive decline, an intermittent dosing regimen of dasatinib with quercetin—a “senolytic” treatment—was found to be safe and well-tolerated. The regimen was also associated with modest increases in Montreal Cognitive Assessment (MoCA) scores. One notable finding from this uncontrolled study was that lower TNF- α levels were linked with cognitive improvement [185].

Curcumin also appears to hold promise. A recent meta-analysis of 12 RCTs involving nearly 500 participants concluded that curcumin supplementation significantly enhanced global cognition, with a standardized mean difference (SMD) of approximately 0.82 and a *p*-value of 0.01. This effect was most pronounced after 24 weeks or more of supplementation, particularly in older adults and in formulations with enhanced bioavailability. The cognitive effects of curcumin are attributed to its potent antioxidant and anti-inflammatory properties, including scavenging free radicals and suppressing neuroinflammation, thereby inhibiting A β aggregation and tau phosphorylation [186].

Similarly, resveratrol—a polyphenol found in grapes and red wine—has been evaluated in clinical trials. In a 2023 meta-analysis of five AD studies totaling 271 patients, resveratrol significantly improved functional Activities of Daily Living (ADL) scores, with an SMD of 0.51, and enhanced A β 40 clearance. However, standard cognitive assessments such as the MMSE did not show improvement [187]. The neuroprotective effects of resveratrol are mediated through SIRT1 activation and inhibition of oxidative and inflammatory signaling pathways [188]. These findings suggest that diet-derived polyphenols, whether obtained from whole foods such as turmeric, berries, nuts, tea, and red wine, or through high-dose supplements, may offer small improvements in cognition or daily function by restoring redox and inflammatory balance.

Diets rich in vitamins and carotenoids have also been investigated. Lutein and zeaxanthin, found in leafy greens, egg yolks, and corn, accumulate in the eyes and brain, where their potent antioxidant and anti-inflammatory effects are well established. In a six-month RCT, older adults with mild cognitive complaints who received a daily supplement of 10 mg lutein and 2 mg zeaxanthin showed improved visual episodic memory and learning compared to placebo [189]. Observational studies have also reported that patients with AD have lower plasma carotenoid levels—including lycopene, α - β -carotene, lutein, and zeaxanthin—relative to controls. Low carotenoid status is additionally associated with an increased risk of mild cognitive impairment (MCI) and AD [190].

Antioxidant vitamins have been a major focus of AD-related trials. High consumption of vitamin E (α -tocopherol) appears particularly protective. A meta-analysis of 15 studies found a 20–22% reduction in the risk of dementia and AD among individuals with high dietary or supplemental vitamin E intake compared to those with low intake [191]. In patients with mild to moderate AD, supplementation with 2000 IU/day α -tocopherol significantly slowed functional decline by 19% per year compared to placebo. In a cohort of 561 individuals, the annual reduction in ADL scores was approximately 3.2 points lower in the vitamin E group—equivalent to a delay of roughly six months in disease progression [192]. Mechanistically, vitamin E functions as a lipid-soluble antioxidant and neuroprotectant capable of intercepting free radicals and dampening neuroinflammation [191].

Recent meta-analyses indicate that B-vitamin supplementation (folate, B12, and B6) can modestly slow cognitive decline. B-vitamins were associated with small improvements in MMSE scores, with a mean difference of approximately +0.14, particularly in long-duration interventions and in individuals without dementia diagnoses. Higher folate intake has also been linked to reduced dementia risk, with a hazard ratio (HR) of approximately 0.61 [193].

Melatonin, an endogenous sleep hormone, also exhibits potent antioxidant and anti-inflammatory activity. Reduced nocturnal melatonin levels have been epidemiologically linked to increased AD risk. Recent meta-analyses of melatonin administration in AD patients demonstrate modest cognitive benefits. One trial reported that AD patients treated with melatonin for more than 12 weeks, typically at doses of 3 mg/day or less, showed improvements in MMSE scores, especially those with mild AD. A network meta-analysis of approximately 50 trials and 20,000 participants found that 6–12 months of low-dose melatonin (≤ 3 mg/day) produced slight cognitive improvements. These effects are attributed to melatonin's free-radical-scavenging capabilities, upregulation of antioxidant enzymes, and modulation of amyloid and tau processing. Melatonin has been highlighted for its high bioavailability, capacity to neutralize free radicals, and chronobiotic neuroprotective effects [194].

Additional antioxidants are under investigation. In AD models, the selenium-containing compound ebselen restored mitochondrial bioenergetics, reduced neuroinflammation, and improved memory [195]. Likewise, silibinin—one of the active components of *Silybum marianum* (milk thistle)—has shown anti-inflammatory and neurotrophic effects in preclinical AD models, though clinical data remain limited. Another candidate is chlorogenic acid (CGA), found in coffee. However, a recent systematic review reported that acute or chronic CGA intake did not significantly improve cognition in RCTs, suggesting that CGA may require a synergistic dietary context—such as whole-coffee matrix effects—to exert cognitive benefits [196].

Functional-food approaches are best represented by dietary patterns that combine multiple bioactive molecules. The Mediterranean diet (MeDi), rich in vegetables, fruits, whole grains, nuts, fish, and olive oil, provides a broad spectrum of antioxidants, polyphenols, and anti-inflammatory lipids. A meta-analysis of over 65,000 individuals found that adherence to the MeDi was associated with an 11–27% reduction in dementia risk, with pooled odds ratios (ORs) of approximately 0.89 for all-cause dementia and 0.73 for AD [197]. A 2025 meta-analysis of 23 cohort studies similarly reported that high adherence to the MeDi reduced the risk of cognitive impairment (HR \approx 0.82, 95% CI 0.75–0.89) and AD (HR \approx 0.70, 0.60–0.82). Thus, strong adherence to the MeDi confers a 11–30% risk reduction for cognitive decline and dementia [198].

Mediterranean-type diets have also demonstrated cognitive benefits in interventional trials. In the >6-year

PREDIMED study, older adults at high vascular risk who were randomized to a MeDi enriched with extra-virgin olive oil or nuts showed significantly higher MMSE scores compared to those on a low-fat diet. Mean MMSE was approximately 0.6 points higher in both MeDi groups ($p \leq 0.015$) after 6.5 years [168]. Conversely, a recent three-year RCT of the MIND diet—a hybrid of the MeDi and DASH diets—in cognitively normal but at-risk older adults reported no significant difference in cognitive decline compared to a calorie-restricted control diet, highlighting the importance of adherence duration and baseline diet quality [199].

Nevertheless, Mediterranean-style diets naturally promote oxido-inflammatory balance through the inclusion of foods rich in quercetin (onions, apples), curcumin (turmeric), carotenoids and vitamins (colorful fruits and vegetables), resveratrol (grapes, wine), and anti-inflammatory lipids (olive oil, fish oils). In summary, clinical data from single-compound supplement trials and large dietary interventions suggest that prioritizing whole dietary patterns rich in these bioactive compounds can support cognitive health by counteracting oxidative stress and inflammation. Although individual trial outcomes may vary, meta-analyses consistently demonstrate small yet significant cognitive or functional improvements with long-term supplementation or high-antioxidant diets. As summarized in Table 2, these findings support the potential role of functional dietary therapies in AD prevention and management [168–199].

5.14. Comparison of Existing Treatments for AD and Functional Dietary Approaches

A multifaceted therapeutic approach is necessary for AD to slow the disease's progression and lessen its symptoms [200]. The current treatments for AD are primarily focused on symptom relief and the targeting of specific pathological biomarkers, such as tau phosphorylation, A β aggregation, and AChE activity. However, these treatments typically have serious drawbacks, including short-term efficacy, adverse effects, and a relatively small influence on the course of the disease [3, 87].

The basis of AD treatment has been symptomatic measures like NMDA receptor antagonists and AChEIs. By blocking AChE, medications such as donepezil, galantamine, and rivastigmine raise acetylcholine levels in synapses, which improves cognitive abilities. However, these medications only offer short-term relief and are frequently linked to gastrointestinal adverse effects, including diarrhea and nausea [86]. Similarly, memantine and other NMDA receptor antagonists reduce excitotoxicity but are not very effective at stopping the progression of the disease [87]. β -secretase (BACE) inhibitors and γ -secretase inhibitors are two strategies that target A β and work to reduce the formation of A β plaques by interfering with the amyloidogenic pathway. Despite their initial promise, the majority of these inhibitors, such as semagacestat and verubecestat, have failed clinical trials because they either do not improve

cognition or have negative side effects like skin cancer and cognitive decline [93, 94]. There have also been no notable clinical benefits from attempts to use drugs like tramiprosate to prevent A β aggregation [201].

On the other hand, the use of bioactive food compounds with anti-inflammatory and antioxidant qualities as dietary-based approaches alongside traditional therapies to combat neurodegenerative disorders may hold promise for AD patients. Dietary therapy provides a multi-targeted strategy that targets the underlying mechanisms of AD, in contrast to pharmaceutical interventions (see Table 3 for a summary of functional food mechanisms) [2-169]. By limiting oxidative stress and inflammation and modulating important signaling pathways implicated in the pathophysiology of AD, polyphenolic compounds have shown neuroprotective qualities [202, 203]. For example, quercetin scavenged free radicals and reduced malondialdehyde levels, a crucial biomarker of lipid peroxidation, thereby limiting oxidative damage [203]. Quercetin can activate AMPK, which is responsible for its neuroprotective effects in AD.

This is because AMPK inhibits the NF- κ B pathway, which lowers oxidative stress and pro-inflammatory cytokine production in the brain. Additionally, quercetin provides strong neuroprotection by preventing the activation of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, a protein complex that triggers inflammatory reactions [141]. Curcumin, another compound of promise, can penetrate the BBB and inhibit GSK-3 β , which further supports its role as a therapeutic agent in AD [204]. Resveratrol provides a variety of benefits by activating Silent Information Regulator 1 (SIRT1), which protects neurons from oxidative stress, suppresses inflammation by inhibiting NF- κ B, and inhibits A β toxicity. It also strengthens antioxidant defenses through Nrf2, modulates pathways like Mammalian Target of Rapamycin (mTOR) and cyclic AMP Response Element-Binding Protein-Brain-Derived Neurotrophic Factor (CREB-BDNF) to improve memory and reduce neurodegeneration, and regulates apoptosis by altering tumor protein 53 (p53) and Forkhead Box O (FOXO) pathways while improving autophagy [205].

Table 2. Functional foods and cognitive health: Clinical findings.

Functional Food / Compound	Key Clinical Findings	References
Quercetin	A 24-week study in older adults found that taking a quercetin-rich onion supplement significantly improved scores on a common cognitive test (MMSE) A small pilot trial also found modest gains in cognitive scores (MoCA) and reduced inflammation.	[184, 185]
Curcumin	A review of multiple studies found that curcumin supplements significantly improved overall cognitive function, especially when taken for 24 weeks or longer.	[186]
Resveratrol	A 2023 meta-analysis of trials in Alzheimer's patients showed that resveratrol significantly improved scores on functional daily activities, but did not improve scores on standard cognitive tests such as the MMSE.	[187, 188]
Lutein & Zeaxanthin	A 6-month study in older adults with mild cognitive impairment found that daily supplementation with these compounds significantly improved visual memory and learning. Observational studies also show that people with Alzheimer's disease often have lower levels of these carotenoids.	[189, 190]
Vitamin E (α -tocopherol)	A meta-analysis of studies showed that high intake of Vitamin E was linked to a 20-22% lower risk of dementia. In a specific trial, high-dose Vitamin E was found to slow the functional decline of patients with mild-to-moderate Alzheimer's by 19% per year.	[191, 192]
B-Vitamins (Folate, B12, B6)	Meta-analyses have shown that B-vitamin supplementation provides a small but noticeable benefit in slowing cognitive decline, particularly in people who are not yet demented. Higher folate intake was also linked to a significantly lower risk of dementia.	[193]
Melatonin	Recent reviews of trials have found that melatonin supplements show modest cognitive benefits, especially in patients with mild AD. These effects were typically seen with low doses over at least 12 weeks.	[194]
Mediterranean Diet	Consistently strong evidence shows that high adherence to this diet is associated with a significant reduction in dementia risk, ranging from 11 to 27%. Intervention trials have shown that adopting this diet can lead to higher cognitive scores (MMSE) over several years.	[168, 184, 198]

Abbreviations: MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; AD: Alzheimer's disease.

Table 3. Functional foods and their biochemical mechanisms in AD.

Functional Food	Bioactive Compound	Biochemical Mechanism	References
Tea, apples, berries, grapes, onions	Quercetin (Flavonoid/Polyphenol)	<ul style="list-style-type: none"> • Activates the Nrf2 pathway, upregulating HO-1 to scavenge ROS. • Inhibits NF-κB signaling, reducing pro-inflammatory cytokines (TNF-α, IL-1β). • Alters AChE and BuChE activity to enhance cholinergic transmission. • Activates the AMPK pathway to improve energy metabolism. • Decreases Aβ plaque formation and BACE1-mediated cleavage of APP in animal models. 	[109-117]
Turmeric (<i>Curcuma longa</i>)	Curcumin (Polyphenol)	<ul style="list-style-type: none"> • Activates the Nrf2 pathway, upregulating HO-1. • Inhibits NF-κB activation, thereby reducing the production of inflammatory mediators. • Prevents Aβ aggregation and promotes disintegration of existing fibrils. • Chelates metal ions such as iron and copper to reduce oxidative stress. 	[109, 116, 119-123, 126-128]
Fruits, Vegetables, Seaweeds	Carotenoids (β -carotene, α -carotene, lutein, zeaxanthin, lycopene, β -cryptoxanthin)	<ul style="list-style-type: none"> • Neutralizes ROS, reducing oxidative damage to neural cells. • Inhibits NF-κB activation. • May influence tau phosphorylation and Aβ aggregation. 	[2, 129-131]
Various foods (almonds, fatty fish, bananas, leafy greens)	Vitamins (E, D, B6, B9, B12)	<ul style="list-style-type: none"> • Vitamin E shields neuronal membranes from oxidative damage. • Vitamin D positively influences cognitive function and modulates Aβ-related biomarkers. • B Vitamins decrease brain atrophy by regulating homocysteine levels, which are associated with AD risk. 	[2, 132-138]
Grapes, peanuts, cranberries, blueberries	Resveratrol (Polyphenol)	<ul style="list-style-type: none"> • Activates the brain's antioxidant systems (<i>e.g.</i>, glutathione, SOD2). • Reduces astrocyte and microglial activation and prevents the synthesis of pro-inflammatory factors. 	[129, 139-142]
Selenium-rich foods (Brazil nuts, meats, seafood, eggs)	Ebselen (Selenium-containing compound)	<ul style="list-style-type: none"> • Exhibits glutathione peroxidase-like effects, scavenging free radicals. • Regulates microglial activation and prevents the synthesis of pro-inflammatory cytokines. • Inhibits cerebral AChE activity. 	[10, 129, 143-147]
Tomatoes, olives, barley, rice, walnuts	Melatonin (Peptide hormone)	<ul style="list-style-type: none"> • Regulates sleep and circadian rhythm disruptions. • Exerts neuroprotective effects in microglial cells. • Lowers the synthesis of tau and Aβ. 	[129, 148-152]
Milk thistle seeds, herbal teas	Silibinin (Antioxidant)	<ul style="list-style-type: none"> • Inhibits AChE activity and Aβ peptide accumulation. • Scavenges ROS and inhibits the release of pro-inflammatory cytokines (TNF-α, IL-1β) and microglial activation. 	[150, 153-157]
Fruits, vegetables	Chlorogenic acid (Phenolic acid)	<ul style="list-style-type: none"> • Scavenges free radicals effectively. • Modulates and inhibits pro-inflammatory cytokines. • Lowers Aβ deposition and reduces neuroinflammation in animal models. 	[158-164]
Mediterranean Diet (Olive oil, fish, fruits, vegetables, nuts, whole grains)	Vitamins C & E, Carotenoids, Polyphenols, Omega-3 fatty acids, Monounsaturated fats	<ul style="list-style-type: none"> • Scavenges free radicals and reduces oxidative damage. • Decreases inflammatory markers such as IL-6 and CRP. 	[165-169]

Abbreviations: Nrf2: Nuclear factor erythroid 2-related factor 2; HO-1: Heme oxygenase-1; ROS: Reactive oxygen species; NF- κ B: Nuclear factor kappa-light-chain-enhancer of activated B cells; TNF- α : Tumor necrosis factor-alpha; IL-1 β : Interleukin-1 beta; AChE: Acetylcholinesterase; BuChE: Butyrylcholinesterase; AMPK: AMP-activated protein kinase; A β : Amyloid-beta; BACE1: Beta-site amyloid precursor protein cleaving enzyme 1; APP: Amyloid precursor protein; AD: Alzheimer's disease; SOD2: Superoxide dismutase 2; IL-6: Interleukin-6; CRP: C-reactive protein.

Dietary interventions incorporating bioactive compounds such as quercetin, curcumin, and resveratrol have gained significant attention for their neuroprotective properties in AD treatments, as these naturally occurring polyphenols are generally associated with fewer and less

severe side effects compared to traditional pharmacological therapies [91-183]. Turmeric's active ingredient, curcumin, is safe in food and has the potential to modulate AD-related pathways. However, using large amounts of supplements may result in mild nausea and

diarrhea, and their iron-chelating qualities may cause subclinical iron deficiency [206]. Quercetin's poor BBB permeability, low bioavailability, and rapid metabolism limit its clinical use, but nanoparticle-based quercetin formulations show promise in improving brain delivery and bioavailability. Quercetin has low toxicity and therapeutic potential, but it may interact with medications through metabolic enzyme modulation [141, 203]. With natural antioxidants like polyphenols demonstrating potential in lowering oxidative stress and enhancing cognitive functions in neurodegenerative diseases, including AD, the significance of dietary and nutrition-based approaches in preventing cognitive decline is becoming more widely acknowledged [207]. The co-administration of donepezil and curcumin, which inhibited cholinergic enzymes, decreased lipid peroxidation, and strengthened antioxidant defenses in dementia models, is an example of how natural compounds and conventional therapies can work synergistically to improve cognitive function [89, 207]. Even though these bioactive substances have therapeutic potential, maximizing benefits while lowering risks requires careful consideration of dosage, bioavailability, and individual medical conditions [208].

Considering their medicinal potential, dietary antioxidants and anti-inflammatory substances may be used as complementary or alternative treatments for AD. These substances not only reduce symptoms but also show promise in delaying the progression of the disease by focusing on several biomarkers, including inflammation and oxidative stress [209]. Additionally, the application of dietary compounds is consistent with personalized medicine principles, enabling customized interventions according to each person's unique metabolic and nutritional profile [178, 210]. This comprehensive approach not only treats the disease's symptoms but also addresses its root causes, paving the way for a more well-rounded and effective AD treatment.

CONCLUSION AND FUTURE DIRECTIONS

While symptoms, course, susceptibility to risk factors, and response to treatment vary widely with AD, there exist specific biochemical mechanisms that underlie this neurodegenerative disorder, with the most ancient and widely recognized theory being the cholinergic hypothesis. The pathogenesis of AD is linked to additional neuropathological elements, such as the generation of A β plaques and the formation of NFTs from tau proteins. Additionally, there is mounting evidence that chronic inflammation and oxidative stress are central drivers of neuronal damage in AD. Although several medications have been developed to treat the disease's symptoms, the majority of these therapeutic drugs are known to have adverse effects, and a significant number have failed clinical trials. However, given the detrimental role that oxidative stress and inflammation play in AD pathogenesis, numerous studies have demonstrated that a range of anti-inflammatory and antioxidant diets can delay the onset of AD by preventing the generation of ROS, modulating pro-inflammatory cytokines, and influencing other pathological

pathways. They may also contribute to better cognitive outcomes or slow cognitive decline in individuals at risk or with early AD. Collectively, the oxido-inflammatory balance could be explored as a new treatment strategy for AD.

Building on the potential of dietary interventions, the goals of future research should be to improve these strategies, investigate ways in which they can work in combination with current treatments, and confirm their effectiveness through extensive, long-term clinical trials. Significantly, future studies also must transcend significant translational challenges: the bioavailability of many functional food-derived compounds is impaired by insufficient absorption, extensive metabolism, or inadequate brain penetration; dose optimization is unclear, with preclinical and clinically achievable doses being discordant; and regulatory approval is difficult due to the absence of uniform standards for safety, efficacy, and quality controls compared with traditional drugs. By addressing these challenges and taking advantage of advances in precision nutrition and innovative delivery systems, future research can realize the full therapeutic promise of dietary interventions, molding them into effective, evidence-based prevention and treatment strategies for AD.

AUTHORS' CONTRIBUTIONS

The authors confirm contribution to the paper as follows: O.S.A.: Conceived the project; C.A.A.: Gathered resource materials and wrote the original manuscript under the supervision of OSA; O.S.A. and M.A.A.: Critically reviewed and edited the manuscript. All authors agreed to the final version.

LIST OF ABBREVIATIONS

AD	= Alzheimer's Disease
A β	= Amyloid-beta
AChEIs	= Acetylcholinesterase Inhibitors
APP	= Amyloid Precursor Protein
APOE	= Apolipoprotein E
ARIA	= Amyloid-Related Imaging Abnormalities
BBB	= Blood-Brain Barrier
BACE1	= β -Site APP-Cleaving Enzyme 1
CNS	= Central Nervous System
CSF	= Cerebrospinal Fluid
GSK-3 β	= Glycogen Synthase Kinase 3 Beta
MeDi	= Mediterranean Diet
MMSE	= Mini-Mental State Examination
NFTs	= Neurofibrillary Tangles
NMDA	= N-methyl-D-aspartate
NSAIDs	= Non-steroidal Anti-inflammatory Drugs
Nrf2	= Nuclear Factor Erythroid 2-related Factor 2

ROS = Reactive Oxygen Species
 SIRT1 = Silent Information Regulator 1
 TLRs = Toll-like Receptors

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

Dr. Adeyemi is the Associate Editorial Board Member of The Open Biochemistry Journal.

ACKNOWLEDGEMENTS

Department of Biochemistry, Bowen University, Iwo, Nigeria.

REFERENCES

- [1] Agnello, L.; Ciaccio, M. Neurodegenerative diseases: From molecular basis to therapy. *Int. J. Mol. Sci.*, **2022**, 23(21), 12854. <http://dx.doi.org/10.3390/ijms232112854> PMID: 36361643
- [2] Varesi, A.; Campagnoli, L.I.M.; Carrara, A.; Pola, I.; Floris, E.; Ricevuti, G.; Chirumbolo, S.; Pascale, A. Non-enzymatic antioxidants against Alzheimer's disease: Prevention, diagnosis and therapy. *Antioxidants*, **2023**, 12(1), 180. <http://dx.doi.org/10.3390/antiox12010180> PMID: 36671042
- [3] Breijyeh, Z.; Karaman, R. Comprehensive review on Alzheimer's disease: Causes and treatment. *Molecules*, **2020**, 25(24), 5789. <http://dx.doi.org/10.3390/molecules25245789> PMID: 33302541
- [4] Maresova, P.; Komarkova, L.; Kuhnova, J.; Cimler, R.; Pazitny, P.; Kandilaki, D.; Musilek, K.; Truhlarova, Z.; Zemek, F.; Kuca, K. Anticipated social and healthcare economic burden of people with Alzheimer's disease in two selected regions of the Czech Republic. *Healthcare*, **2020**, 8(4), 433. <http://dx.doi.org/10.3390/healthcare8040433> PMID: 33114626
- [5] Sadigh-Eteghad, S.; Sabermarouf, B.; Majdi, A.; Talebi, M.; Farhoudi, M.; Mahmoudi, J. Amyloid-beta: A crucial factor in Alzheimer's disease. *Med. Princ. Pract.*, **2015**, 24(1), 1-10. <http://dx.doi.org/10.1159/000369101> PMID: 25471398
- [6] Kumar, A.; Sidhu, J.; Goyal, A.; Tsao, J.W.; Svercauski, J. Alzheimer disease (nursing). In: *StatPearls*; StatPearls Publishing: Treasure Island, **2021**.
- [7] Guzman-Martinez, L.; Maccioni, R.B.; Farías, G.A.; Fuentes, P.; Navarrete, L.P. Biomarkers for Alzheimer's disease. *Curr. Alzheimer Res.*, **2019**, 16(6), 518-528. <http://dx.doi.org/10.2174/1567205016666190517121140> PMID: 31099321
- [8] Scheltens, P.; De Strooper, B.; Kivipelto, M.; Holstege, H.; Chételat, G.; Teunissen, C.E.; Cummings, J.; van der Flier, W.M. Alzheimer's disease. *Lancet*, **2021**, 397(10284), 1577-1590. [http://dx.doi.org/10.1016/S0140-6736\(20\)32205-4](http://dx.doi.org/10.1016/S0140-6736(20)32205-4) PMID: 33667416
- [9] Ionescu-Tucker, A.; Cotman, C.W. Emerging roles of oxidative stress in brain aging and Alzheimer's disease. *Neurobiol. Aging*, **2021**, 107, 86-95. <http://dx.doi.org/10.1016/j.neurobiolaging.2021.07.014> PMID: 34416493
- [10] Collins, A.E.; Saleh, T.M.; Kalisch, B.E. Naturally occurring antioxidant therapy in Alzheimer's disease. *Antioxidants*, **2022**, 11(2), 213. <http://dx.doi.org/10.3390/antiox11020213> PMID: 35204096
- [11] Zhang, W.; Xiao, D.; Mao, Q.; Xia, H. Role of neuroinflammation in neurodegeneration development. *Signal Transduct. Target. Ther.*, **2023**, 8(1), 267. <http://dx.doi.org/10.1038/s41392-023-01486-5> PMID: 37433768
- [12] Teleanu, D.M.; Niculescu, A.G.; Lungu, I.I.; Radu, C.I.; Vladăncenco, O.; Roza, E.; Costăchescu, B.; Grumezescu, A.M.; Teleanu, R.I. An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. *Int. J. Mol. Sci.*, **2022**, 23(11), 5938. <http://dx.doi.org/10.3390/ijms23115938> PMID: 35682615
- [13] Fessel, J. Formulating treatment to cure Alzheimer's dementia: Approach #2. *Int. J. Mol. Sci.*, **2024**, 25(6), 3524. <http://dx.doi.org/10.3390/ijms25063524> PMID: 38542495
- [14] Rukmangadachar, LA; Bollu, PC Amyloid beta peptide. In: *StatPearls*; StatPearls Publishing: Treasure Island, **2025**.
- [15] Zhang, F.; Zhong, R.; Cheng, C.; Li, S.; Le, W. New therapeutics beyond amyloid- β and tau for the treatment of Alzheimer's disease. *Acta Pharmacol. Sin.*, **2021**, 42(9), 1382-1389. <http://dx.doi.org/10.1038/s41401-020-00565-5> PMID: 33268824
- [16] Shoaib, S.; Ansari, M.A.; Fatease, A.A.; Safhi, A.Y.; Hani, U.; Jahan, R.; Alomary, M.N.; Ansari, M.N.; Ahmed, N.; Wahab, S.; Ahmad, W.; Yusuf, N.; Islam, N. Plant-derived bioactive compounds in the management of neurodegenerative disorders: Challenges, future directions and molecular mechanisms involved in neuroprotection. *Pharmaceutics*, **2023**, 15(3), 749. <http://dx.doi.org/10.3390/pharmaceutics15030749> PMID: 36986610
- [17] Dar, R.A.; Shah Nawaz, M.; Ahanger, M.A.; Majid, I. Exploring the diverse bioactive compounds from medicinal plants: A review. *J. Phytopharmacol.*, **2023**, 12(3), 189-195. <http://dx.doi.org/10.31254/phyto.2023.12307>
- [18] Babazadeh, A.; Vahed, F.M.; Liu, Q.; Siddiqui, S.A.; Kharazmi, M.S.; Jafari, S.M. Natural bioactive molecules as neuromedicines for the treatment/prevention of neurodegenerative diseases. *ACS Omega*, **2023**, 8(4), 3667-3683. <http://dx.doi.org/10.1021/acsomega.2c06098> PMID: 36743024
- [19] Sehar, U.; Rawat, P.; Reddy, A.P.; Kopel, J.; Reddy, P.H. Amyloid beta in aging and Alzheimer's disease. *Int. J. Mol. Sci.*, **2022**, 23(21), 12924. <http://dx.doi.org/10.3390/ijms232112924> PMID: 36361714
- [20] Orobets, K.S.; Karamyshev, A.L. Amyloid precursor protein and Alzheimer's disease. *Int. J. Mol. Sci.*, **2023**, 24(19), 14794. <http://dx.doi.org/10.3390/ijms241914794> PMID: 37834241
- [21] Sirisi, S.; Sánchez-Aced, É.; Belbin, O.; Lleó, A. APP dyshomeostasis in the pathogenesis of Alzheimer's disease: Implications for current drug targets. *Alzheimers Res. Ther.*, **2024**, 16(1), 144. <http://dx.doi.org/10.1186/s13195-024-01504-w> PMID: 38951839
- [22] Tijms, B.M.; Vermunt, L.; Zwan, M.D.; van Harten, A.C.; van der Flier, W.M.; Teunissen, C.E.; Scheltens, P.; Visser, P.J. Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. *Ann. Clin. Transl. Neurol.*, **2018**, 5(9), 1037-1047. <http://dx.doi.org/10.1002/acn3.615> PMID: 30250861
- [23] Garbuz, D.G.; Zatssepina, O.G.; Evgen'ev, M.B. Beta amyloid, tau protein, and neuroinflammation: An attempt to integrate different hypotheses of Alzheimer's disease pathogenesis. *Mol. Biol.*, **2021**, 55(5), 734-747. <http://dx.doi.org/10.31857/S0026898421050049> PMID: 34671002
- [24] Chen, G.; Xu, T.; Yan, Y.; Zhou, Y.; Jiang, Y.; Melcher, K.; Xu, H.E. Amyloid beta: Structure, biology and structure-based therapeutic development. *Acta Pharmacol. Sin.*, **2017**, 38(9), 1205-1235. <http://dx.doi.org/10.1038/aps.2017.28> PMID: 28713158
- [25] Ashrafian, H.; Zadeh, E.H.; Khan, R.H. Review on Alzheimer's disease: Inhibition of amyloid beta and tau tangle formation. *Int. J. Biol. Macromol.*, **2021**, 167, 382-394. <http://dx.doi.org/10.1016/j.ijbiomac.2020.11.192> PMID: 33278431
- [26] Reiss, A.B.; Arain, H.A.; Stecker, M.M.; Siegart, N.M.; Kasselmann, L.J. Amyloid toxicity in Alzheimer's disease. *Rev. Neurosci.*, **2018**, 29(6), 613-627. <http://dx.doi.org/10.1515/revneuro-2017-0063> PMID: 29447116
- [27] Aziz, N.; Wal, P.; Singh, Y.K.; Kumar, P.; Singh, B. A comprehensive and concise review on significance of potent

- peptide; Amyloid beta (A β) in progression of Alzheimer's disease. *Curr. Drug Ther.*, **2024**, *20*
<http://dx.doi.org/10.2174/0115748855299317241014051505>
- [28] Rudajev, V.; Novotny, J. The role of lipid environment in ganglioside GM1-induced amyloid β aggregation. *Membranes*, **2020**, *10*(9), 226.
<http://dx.doi.org/10.3390/membranes10090226> PMID: 32916822
- [29] Wiatrak, B.; Piasny, J.; Kuźniarski, A.; Gąsiorowski, K. Interactions of amyloid- β with membrane proteins. *Int. J. Mol. Sci.*, **2021**, *22*(11), 6075.
<http://dx.doi.org/10.3390/ijms22116075> PMID: 34199915
- [30] Akyuz, E.; Arulsamy, A.; Aslan, F.S.; Sarisözen, B.; Guney, B.; Hekimoglu, A.; Yilmaz, B.N.; Retinasamy, T.; Shaikh, M.F. An expanded narrative review of neurotransmitters on Alzheimer's disease: The role of therapeutic interventions on neurotransmission. *Mol. Neurobiol.*, **2025**, *62*(2), 1631-1674.
<http://dx.doi.org/10.1007/s12035-024-04333-y> PMID: 39012443
- [31] Siddiqui, A.J.; Badraoui, R.; Jahan, S.; Alshahrani, M.M.; Siddiqui, M.A.; Khan, A.; Adnan, M. Targeting NMDA receptor in Alzheimer's disease: Identifying novel inhibitors using computational approaches. *Front. Pharmacol.*, **2023**, *14*, 1208968.
<http://dx.doi.org/10.3389/fphar.2023.1208968> PMID: 37416066
- [32] Oz, M.; Lorke, D.; Yang, K.H.; Petroianu, G. On the interaction of β -amyloid peptides and α 7-nicotinic acetylcholine receptors in Alzheimer's disease. *Curr. Alzheimer Res.*, **2013**, *10*(6), 618-630.
<http://dx.doi.org/10.2174/15672050113109990132> PMID: 23627750
- [33] Mietelska-Porowska, A.; Wasik, U.; Goras, M.; Filipiek, A.; Niewiadomska, G. Tau protein modifications and interactions: Their role in function and dysfunction. *Int. J. Mol. Sci.*, **2014**, *15*(3), 4671-4713.
<http://dx.doi.org/10.3390/ijms15034671> PMID: 24646911
- [34] Zhu, L.; Qian, Z. Recent studies of atomic-resolution structures of tau protein and structure-based inhibitors. *Quant. Biol.*, **2022**, *10*(1), 17-34.
<http://dx.doi.org/10.15302/j-QB-021-0271>
- [35] Mummery, C.J.; Börjesson-Hanson, A.; Blackburn, D.J.; Vijverberg, E.G.B.; De Deyn, P.P.; Ducharme, S.; Jonsson, M.; Schneider, A.; Rinne, J.O.; Ludolph, A.C.; Bodenschatz, R.; Kordasiewicz, H.; Swayze, E.E.; Fitzsimmons, B.; Mignon, L.; Moore, K.M.; Yun, C.; Baumann, T.; Li, D.; Norris, D.A.; Crean, R.; Graham, D.L.; Huang, E.; Ratti, E.; Bennett, C.F.; Junge, C.; Lane, R.M. Tau-targeting antisense oligonucleotide MAPT_{rx} in mild Alzheimer's disease: A phase 1b, randomized, placebo-controlled trial. *Nat. Med.*, **2023**, *29*(6), 1437-1447.
<http://dx.doi.org/10.1038/s41591-023-02326-3> PMID: 37095250
- [36] Rodrigues, S.; Anglada-Huguet, M.; Hochgräfe, K.; Kaniyappan, S.; Wegmann, S.; Mandelkow, E.M. Spreading of tau protein does not depend on aggregation propensity. *J. Mol. Neurosci.*, **2023**, *73*(9-10), 693-712.
<http://dx.doi.org/10.1007/s12031-023-02143-w> PMID: 37606769
- [37] Alquezar, C.; Arya, S.; Kao, A.W. Tau post-translational modifications: Dynamic transformers of tau function, degradation, and aggregation. *Front. Neurol.*, **2021**, *11*, 595532.
<http://dx.doi.org/10.3389/fneur.2020.595532> PMID: 33488497
- [38] Saha, P.; Sen, N. Tauopathy: A common mechanism for neurodegeneration and brain aging. *Mech. Ageing Dev.*, **2019**, *178*, 72-79.
<http://dx.doi.org/10.1016/j.mad.2019.01.007> PMID: 30668956
- [39] Wang, Y.; Mandelkow, E. Tau in physiology and pathology. *Nat. Rev. Neurosci.*, **2016**, *17*(1), 22-35.
<http://dx.doi.org/10.1038/nrn.2015.1> PMID: 26631930
- [40] Hernández, F.; Llorens-Martín, M.; Bolós, M.; Pérez, M.; Cuadros, R.; Pallas-Bazarra, N.; Zabala, J.C.; Avila, J. New beginnings in Alzheimer's disease: The most prevalent tauopathy. *J. Alzheimers Dis.*, **2018**, *64*(s1), S529-S534.
<http://dx.doi.org/10.3233/JAD-179916> PMID: 29562521
- [41] Jouanne, M.; Rault, S.; Voisin-Chiret, A.S. Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents. *Eur. J. Med. Chem.*, **2017**, *139*, 153-167.
<http://dx.doi.org/10.1016/j.ejmech.2017.07.070> PMID: 28800454
- [42] Nizynski, B.; Dzwolak, W.; Nieznanski, K. Amyloidogenesis of Tau protein. *Protein Sci.*, **2017**, *26*(11), 2126-2150.
<http://dx.doi.org/10.1002/pro.3275> PMID: 28833749
- [43] Sergeant, N.; Vingtdoux, V.; Eddarkaoui, S.; Gay, M.; Evrard, C.; Le Fur, N.; Laurent, C.; Caillierez, R.; Obriot, H.; Larchanché, P.E.; Farce, A.; Coevoet, M.; Carato, P.; Kouach, M.; Descat, A.; Dallemagne, P.; Buée-Scherrer, V.; Blum, D.; Hamdane, M.; Buée, L.; Melnyk, P. New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. *Neurobiol. Dis.*, **2019**, *129*, 217-233.
<http://dx.doi.org/10.1016/j.nbd.2019.03.028> PMID: 30928644
- [44] Luan, K.; Rosales, J.L.; Lee, K.Y. Viewpoint: Crosstalks between neurofibrillary tangles and amyloid plaque formation. *Ageing Res. Rev.*, **2013**, *12*(1), 174-181.
<http://dx.doi.org/10.1016/j.arr.2012.06.002> PMID: 22728532
- [45] Tautou, M.; Eddarkaoui, S.; Descamps, F.; Larchanché, P.E.; El Bakali, J.; Goveas, L.M.; Dumoulin, M.; Lamarre, C.; Blum, D.; Buée, L.; Melnyk, P.; Sergeant, N. A β -secretase modulator decreases tau pathology and preserves short-term memory in a mouse model of neurofibrillary degeneration. *Front. Pharmacol.*, **2021**, *12*, 679335.
<http://dx.doi.org/10.3389/fphar.2021.679335> PMID: 34267657
- [46] Jellinger, K.A. Neuropathological assessment of the Alzheimer spectrum. *J. Neural Transm.*, **2020**, *127*(9), 1229-1256.
<http://dx.doi.org/10.1007/s00702-020-02232-9> PMID: 32740684
- [47] Lewczuk, P.; Riederer, P.; O'Bryant, S.E.; Verbeek, M.M.; Dubois, B.; Visser, P.J.; Jellinger, K.A.; Engelborghs, S.; Ramirez, A.; Parnetti, L.; Jack, C.R., Jr; Teunissen, C.E.; Hampel, H.; Lleó, A.; Jessen, F.; Glodzik, L.; de Leon, M.J.; Fagan, A.M.; Molinuevo, J.L.; Jansen, W.J.; Winblad, B.; Shaw, L.M.; Andreasson, U.; Otto, M.; Mollenhauer, B.; Wiltfang, J.; Turner, M.R.; Zerr, I.; Handels, R.; Thompson, A.G.; Johansson, G.; Ermann, N.; Trojanowski, J.Q.; Karaca, I.; Wagner, H.; Oeckl, P.; van Waalwijk van Doorn, L.; Bjerke, M.; Kapogiannis, D.; Kuiperij, H.B.; Farotti, L.; Li, Y.; Gordon, B.A.; Epelbaum, S.; Vos, S.J.B.; Klijn, C.J.M.; Van Nostrand, W.E.; Minguillon, C.; Schmitz, M.; Gallo, C.; Lopez Mato, A.; Thibaut, F.; Lista, S.; Alcolea, D.; Zetterberg, H.; Blennow, K.; Kornhuber, J. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the consensus of the task force on biological markers in psychiatry of the world federation of societies of biological psychiatry. *World J. Biol. Psychiatry*, **2018**, *19*(4), 244-328.
<http://dx.doi.org/10.1080/15622975.2017.1375556> PMID: 29076399
- [48] Chen, Z.R.; Huang, J.B.; Yang, S.L.; Hong, F.F. Role of cholinergic signaling in Alzheimer's disease. *Molecules*, **2022**, *27*(6), 1816.
<http://dx.doi.org/10.3390/molecules27061816> PMID: 35335180
- [49] Žnidaršič, N.; Štrbenc, M.; Grgurevič, N.; Snoj, T. Potential revival of cholinesterase inhibitors as drugs in veterinary medicine. *Front. Vet. Sci.*, **2023**, *10*, 1125618.
<http://dx.doi.org/10.3389/fvets.2023.1125618> PMID: 36937006
- [50] Hampel, H.; Mesulam, M.M.; Cuello, A.C.; Farlow, M.R.; Giacobini, E.; Grossberg, G.T.; Khachaturian, A.S.; Vergallo, A.; Cavado, E.; Snyder, P.J.; Khachaturian, Z.S. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain*, **2018**, *141*(7), 1917-1933.
<http://dx.doi.org/10.1093/brain/awy132> PMID: 29850777
- [51] Berry, A.S.; Harrison, T.M. New perspectives on the basal forebrain cholinergic system in Alzheimer's disease. *Neurosci. Biobehav. Rev.*, **2023**, *150*, 105192.
<http://dx.doi.org/10.1016/j.neubiorev.2023.105192> PMID: 37086935
- [52] Yang, L.; Li, C.; Chen, X.; Wang, J.; Gao, S.; Yang, L.; Zhao, Y.; Wang, H.; Du, Y. Evaluation of spinal cord motor function in

- Alzheimer's disease using electrophysiological techniques indicates association of acetylcholine receptors with the disease. *Int. J. Clin. Exp. Med.*, **2014**, 7(12), 5643-5649. PMID: 25664084
- [53] Chen, X.Q.; Mobley, W.C. Exploring the pathogenesis of Alzheimer disease in basal forebrain cholinergic neurons: Converging insights from alternative hypotheses. *Front. Neurosci.*, **2019**, 13, 446. <http://dx.doi.org/10.3389/fnins.2019.00446> PMID: 31133787
- [54] Martorana, A.; Esposito, Z.; Koch, G. Beyond the cholinergic hypothesis: Do current drugs work in Alzheimer's disease? *CNS Neurosci. Ther.*, **2010**, 16(4), 235-245. <http://dx.doi.org/10.1111/j.1755-5949.2010.00175.x> PMID: 20560995
- [55] Sies, H. Oxidative stress: Concept and some practical aspects. *Antioxidants*, **2020**, 9(9), 852. <http://dx.doi.org/10.3390/antiox9090852> PMID: 32927924
- [56] Buccellato, F.R.; D'Anca, M.; Fenoglio, C.; Scarpini, E.; Galimberti, D. Role of oxidative damage in Alzheimer's disease and neurodegeneration: From pathogenic mechanisms to biomarker discovery. *Antioxidants*, **2021**, 10(9), 1353. <http://dx.doi.org/10.3390/antiox10091353> PMID: 34572985
- [57] Jelinek, M.; Jurajda, M.; Duris, K. Oxidative stress in the brain: Basic concepts and treatment strategies in stroke. *Antioxidants*, **2021**, 10(12), 1886. <http://dx.doi.org/10.3390/antiox10121886> PMID: 34942989
- [58] Misrani, A.; Tabassum, S.; Yang, L. Mitochondrial dysfunction and oxidative stress in Alzheimer's disease. *Front. Aging Neurosci.*, **2021**, 13, 617588. <http://dx.doi.org/10.3389/fnagi.2021.617588> PMID: 33679375
- [59] Simpson, D.S.A.; Oliver, P.L. ROS generation in microglia: Understanding oxidative stress and inflammation in neurodegenerative disease. *Antioxidants*, **2020**, 9(8), 743. <http://dx.doi.org/10.3390/antiox9080743> PMID: 32823544
- [60] Martemucci, G.; Costagliola, C.; Mariano, M.; D'andrea, L.; Napolitano, P.; D'Alessandro, A.G. Free radical properties, source and targets, antioxidant consumption and health. *Oxygen*, **2022**, 2(2), 48-78. <http://dx.doi.org/10.3390/oxygen2020006>
- [61] Picca, A.; Calvani, R.; Coelho-Junior, H.J.; Landi, F.; Bernabei, R.; Marzetti, E. Mitochondrial dysfunction, oxidative stress, and neuroinflammation: Intertwined roads to neurodegeneration. *Antioxidants*, **2020**, 9(8), 647. <http://dx.doi.org/10.3390/antiox9080647> PMID: 32707949
- [62] Brambilla, R. Neuroinflammation, the thread connecting neurological disease. *Acta Neuropathol.*, **2019**, 137(5), 689-691. <http://dx.doi.org/10.1007/s00401-019-02009-9> PMID: 30968314
- [63] Chen, Y.; Yu, Y. Tau and neuroinflammation in Alzheimer's disease: Interplay mechanisms and clinical translation. *J. Neuroinflammation*, **2023**, 20(1), 165. <http://dx.doi.org/10.1186/s12974-023-02853-3> PMID: 37452321
- [64] Rodríguez-Gómez, J.A.; Kavanagh, E.; Engskog-Vlachos, P.; Engskog, M.K.R.; Herrera, A.J.; Espinosa-Oliva, A.M.; Joseph, B.; Hajji, N.; Venero, J.L.; Burguillos, M.A. Microglia: Agents of the CNS pro-inflammatory response. *Cells*, **2020**, 9(7), 1717. <http://dx.doi.org/10.3390/cells9071717> PMID: 32709045
- [65] Leng, F.; Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here? *Nat. Rev. Neurol.*, **2021**, 17(3), 157-172. <http://dx.doi.org/10.1038/s41582-020-00435-y> PMID: 33318676
- [66] Pascual, M.; Calvo-Rodríguez, M.; Núñez, L.; Villalobos, C.; Ureña, J.; Guerri, C. Toll-like receptors in neuroinflammation, neurodegeneration, and alcohol-induced brain damage. *IUBMB Life*, **2021**, 73(7), 900-915. <http://dx.doi.org/10.1002/iub.2510> PMID: 34033211
- [67] Galasko, D.; Montine, T.J. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. *Biomarkers Med.*, **2010**, 4(1), 27-36. <http://dx.doi.org/10.2217/bmm.09.89> PMID: 20383271
- [68] Ahmad, S.; Yang, W.; Orellana, A.; Frölich, L.; de Rojas, I.; Cano, A.; Boada, M.; Hernández, I.; Hausner, L.; Harms, A.C.; Bakker, M.H.M.; Cabrera-Socorro, A.; Amin, N.; Ramírez, A.; Ruiz, A.; Van Duijn, C.M.; Hankemeier, T. Association of oxidative stress and inflammatory metabolites with Alzheimer's disease cerebrospinal fluid biomarkers in mild cognitive impairment. *Alzheimers Res. Ther.*, **2024**, 16(1), 171. <http://dx.doi.org/10.1186/s13195-024-01542-4> PMID: 39080778
- [69] Kuo, H.C.; Yen, H.C.; Huang, C.C.; Hsu, W.C.; Wei, H.J.; Lin, C.L. Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer's disease. *Int. J. Neurosci.*, **2015**, 125(10), 747-754. <http://dx.doi.org/10.3109/00207454.2014.971787> PMID: 25290083
- [70] Hesse, R.; Wahler, A.; Gummert, P.; Kirschmer, S.; Otto, M.; Tuman, H.; Lewerenz, J.; Schnack, C.; von Arnim, C.A.F. Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1 β . *BMC Neurol.*, **2016**, 16(1), 185. <http://dx.doi.org/10.1186/s12883-016-0707-z> PMID: 27671345
- [71] Liu, Z.; Liu, Y.; Tu, X.; Shen, H.; Qiu, H.; Chen, H.; He, J. High serum levels of malondialdehyde and 8-OHdG are both associated with early cognitive impairment in patients with acute ischaemic stroke. *Sci. Rep.*, **2017**, 7(1), 9493. <http://dx.doi.org/10.1038/s41598-017-09988-3> PMID: 28842715
- [72] Cioffi, F.; Adam, R.H.I.; Bansal, R.; Broersen, K. A review of oxidative stress products and related genes in early Alzheimer's disease. *J. Alzheimers Dis.*, **2021**, 83(3), 977-1001. <http://dx.doi.org/10.3233/JAD-210497> PMID: 34420962
- [73] Gubandru, M.; Margina, D.; Tsitsimpikou, C.; Goutzourelas, N.; Tsarouhas, K.; Ilie, M.; Tsatsakis, A.M.; Kouretas, D. Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers. *Food Chem. Toxicol.*, **2013**, 61, 209-214. <http://dx.doi.org/10.1016/j.fct.2013.07.013> PMID: 23871825
- [74] Prins, S.; de Kam, M.L.; Teunissen, C.E.; Groeneveld, G.J. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease. *Alzheimers Res. Ther.*, **2022**, 14(1), 106. <http://dx.doi.org/10.1186/s13195-022-01051-2> PMID: 35922871
- [75] Zabel, M.; Nackenoff, A.; Kirsch, W.M.; Harrison, F.E.; Perry, G.; Schrag, M. Markers of oxidative damage to lipids, nucleic acids and proteins and antioxidant enzymes activities in Alzheimer's disease brain: A meta-analysis in human pathological specimens. *Free Radic. Biol. Med.*, **2018**, 115, 351-360. <http://dx.doi.org/10.1016/j.freeradbiomed.2017.12.016> PMID: 29253591
- [76] Sliwinski, A.; Kwiatkowski, D.; Czarny, P.; Toma, M.; Wigner, P.; Drzewoski, J.; Fabianowska-Majewska, K.; Szemraj, J.; Maes, M.; Galecki, P.; Sliwinski, T. The levels of 7,8-dihydrodeoxyguanosine (8-oxoG) and 8-oxoguanine DNA glycosylase 1 (OGG1) - A potential diagnostic biomarkers of Alzheimer's disease. *J. Neurol. Sci.*, **2016**, 368, 155-159. <http://dx.doi.org/10.1016/j.jns.2016.07.008> PMID: 27538622
- [77] Park, J.C.; Han, S.H.; Mook-Jung, I. Peripheral inflammatory biomarkers in Alzheimer's disease: A brief review. *BMB Rep.*, **2020**, 53(1), 10-19. <http://dx.doi.org/10.5483/BMBRep.2020.53.1.309> PMID: 31865964
- [78] Lista, S.; Imbimbo, B.P.; Grasso, M.; Fidilio, A.; Emanuele, E.; Minoretta, P.; López-Ortiz, S.; Martín-Hernández, J.; Gabelle, A.; Caruso, G.; Malaguti, M.; Melchiorri, D.; Santos-Lozano, A.; Imbimbo, C.; Heneka, M.T.; Caraci, F. Tracking neuroinflammatory biomarkers in Alzheimer's disease: A strategy for individualized therapeutic approaches? *J. Neuroinflammation*, **2024**, 21(1), 187. <http://dx.doi.org/10.1186/s12974-024-03163-y> PMID: 39080712
- [79] Edwards, G.A., III; Gamez, N.; Escobedo, G., Jr; Calderon, O.; Moreno-Gonzalez, I. Modifiable risk factors for Alzheimer's disease. *Front. Aging Neurosci.*, **2019**, 11, 146.

- <http://dx.doi.org/10.3389/fnagi.2019.00146> PMID: 31293412
- [80] Ettcheto, M.; Olloquequi, J.; Sánchez-López, E.; Busquets, O.; Cano, A.; Manzone, P.R.; Beas-Zarate, C.; Castro-Torres, R.D.; García, M.L.; Bulló, M.; Auladell, C.; Folch, J.; Camins, A. Benzodiazepines and related drugs as a risk factor in Alzheimer's disease dementia. *Front. Aging Neurosci.*, **2020**, *11*, 344. <http://dx.doi.org/10.3389/fnagi.2019.00344> PMID: 31969812
- [81] Stefaniak, O.; Dobrzyńska, M.; Drzymała-Czyż, S.; Przysławski, J. Diet in the prevention of Alzheimer's disease: Current knowledge and future research requirements. *Nutrients*, **2022**, *14*(21), 4564. <http://dx.doi.org/10.3390/nu14214564> PMID: 36364826
- [82] Silva, M.V.F.; Loures, C.M.G.; Alves, L.C.V.; de Souza, L.C.; Borges, K.B.G.; Carvalho, M.G. Alzheimer's disease: Risk factors and potentially protective measures. *J. Biomed. Sci.*, **2019**, *26*(1), 33. <http://dx.doi.org/10.1186/s12929-019-0524-y> PMID: 31072403
- [83] Khan, T.; Waseem, R.; Shahid, M.; Ansari, J.; Ahanger, I.A.; Hassan, I.; Islam, A. Recent advancement in therapeutic strategies for Alzheimer's disease: Insights from clinical trials. *Ageing Res. Rev.*, **2023**, *92*, 102113. <http://dx.doi.org/10.1016/j.arr.2023.102113> PMID: 37918760
- [84] Athar, T.; Al Balushi, K.; Khan, S.A. Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease. *Mol. Biol. Rep.*, **2021**, *48*(7), 5629-5645. <http://dx.doi.org/10.1007/s11033-021-06512-9> PMID: 34181171
- [85] Vaz, M.; Silvestre, S. Alzheimer's disease: Recent treatment strategies. *Eur. J. Pharmacol.*, **2020**, *887*, 173554. <http://dx.doi.org/10.1016/j.ejphar.2020.173554> PMID: 32941929
- [86] Redman, R.R.; Mackenzie, H.; Dissanayake, K.N.; Eddleston, M.; Ribchester, R.R. Donepezil inhibits neuromuscular junctional acetylcholinesterase and enhances synaptic transmission and function in isolated skeletal muscle. *Br. J. Pharmacol.*, **2022**, *179*(24), 5273-5289. <http://dx.doi.org/10.1111/bph.15940> PMID: 36028305
- [87] Beltagy, D.M.; Nawar, N.F.; Mohamed, T.M.; Tousson, E.; El-Keey, M.M. The synergistic effect of nanocurcumin and donepezil on Alzheimer's via PI3K/AKT/GSK-3 β pathway modulating. *Prostaglandins Other Lipid Mediat.*, **2024**, *170*, 106791. <http://dx.doi.org/10.1016/j.prostaglandins.2023.106791> PMID: 37918555
- [88] Metz, C.N.; Pavlov, V.A. Treating disorders across the lifespan by modulating cholinergic signaling with galantamine. *J. Neurochem.*, **2021**, *158*(6), 1359-1380. <http://dx.doi.org/10.1111/jnc.15243> PMID: 33219523
- [89] Shi, W.; Han, W.; Liao, Y.; Wen, J.; Zhang, G. Inhibition mechanism of fisetin on acetylcholinesterase and its synergistic effect with galantamine. *Spectrochim. Acta A Mol. Biomol. Spectrosc.*, **2024**, *305*, 123452. <http://dx.doi.org/10.1016/j.saa.2023.123452> PMID: 37769468
- [90] Nguyen, K.; Hoffman, H.; Chakkamparambil, B.; Grossberg, G.T. Evaluation of rivastigmine in Alzheimer's disease. *Neurodegener. Dis. Manag.*, **2021**, *11*(1), 35-48. <http://dx.doi.org/10.2217/nmt-2020-0052> PMID: 33198569
- [91] Peng, Y.; Jin, H.; Xue, Y.; Chen, Q.; Yao, S.; Du, M.; Liu, S. Current and future therapeutic strategies for Alzheimer's disease: An overview of drug development bottlenecks. *Front. Aging Neurosci.*, **2023**, *15*, 1206572. <http://dx.doi.org/10.3389/fnagi.2023.1206572> PMID: 37600514
- [92] Madav, Y.; Wairkar, S.; Prabhakar, B. Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease. *Brain Res. Bull.*, **2019**, *146*, 171-184. <http://dx.doi.org/10.1016/j.brainresbull.2019.01.004> PMID: 30634016
- [93] Alshamrani, M. Recent trends in active and passive immunotherapies of Alzheimer's disease. *Antibodies*, **2023**, *12*(2), 41. <http://dx.doi.org/10.3390/antib12020041> PMID: 37366656
- [94] Cummings, J.; Apostolova, L.; Rabinovici, G.D.; Atri, A.; Aisen, P.; Greenberg, S.; Hendrix, S.; Selkoe, D.; Weiner, M.; Petersen, R.C.; Salloway, S. Lecanemab: Appropriate use recommendations. *J. Prev. Alzheimers Dis.*, **2023**, *10*(3), 362-377. <http://dx.doi.org/10.14283/jpad.2023.30> PMID: 37357276
- [95] Vitek, G.E.; Decourt, B.; Sabbagh, M.N. Lecanemab (BAN2401): An anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. *Expert Opin. Investig. Drugs*, **2023**, *32*(2), 89-94. <http://dx.doi.org/10.1080/13543784.2023.2178414> PMID: 36749830
- [96] Chowdhury, S.; Chowdhury, N.S. Novel anti-amyloid-beta (A β) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review. *Int. J. Immunopathol. Pharmacol.*, **2023**, *37*, 03946320231209839. <http://dx.doi.org/10.1177/03946320231209839> PMID: 37902139
- [97] Mintun, M.; Ritchie, C.W.; Solomon, P.; Sims, J.R.; Salloway, S.; Hansson, O.; Apostolova, L.G.; Zimmer, J.A.; Evans, C.D.; Lu, M.; Ardayfio, P.A.; Sparks, J.D.; Wessels, A.M.; Shcherbinin, S.; Wang, H.; Nery, E.S.M.; Collins, E.C.; Dennehy, E.B.; Brooks, D.A.; Skovronsky, D.M. Donanemab in early symptomatic Alzheimer's disease: Efficacy and safety in TRAILBLAZER-ALZ 2, a phase 3 randomized clinical trial. *Alzheimers Dement.*, **2023**, *19*(S24), e082733. <http://dx.doi.org/10.1002/alz.082733>
- [98] Cheng, C.; Wan, H.; Cong, P.; Huang, X.; Wu, T.; He, M.; Zhang, Q.; Xiong, L.; Tian, L. Targeting neuroinflammation as a preventive and therapeutic approach for perioperative neurocognitive disorders. *J. Neuroinflammation*, **2022**, *19*(1), 297. <http://dx.doi.org/10.1186/s12974-022-02656-y> PMID: 36503642
- [99] Liu, P.; Wang, Y.; Sun, Y.; Peng, G. Neuroinflammation as a potential therapeutic target in Alzheimer's disease. *Clin. Interv. Aging*, **2022**, *17*, 665-674. <http://dx.doi.org/10.2147/CIA.S357558> PMID: 35520949
- [100] Knight, E.; Geetha, T.; Broderick, T.L.; Babu, J.R. The role of dietary antioxidants and their potential mechanisms in Alzheimer's disease treatment. *Metabolites*, **2023**, *13*(3), 438. <http://dx.doi.org/10.3390/metabo13030438> PMID: 36984879
- [101] Tchekalarova, J.; Tzoneva, R. Oxidative stress and aging as risk factors for Alzheimer's disease and Parkinson's disease: The role of the antioxidant melatonin. *Int. J. Mol. Sci.*, **2023**, *24*(3), 3022. <http://dx.doi.org/10.3390/ijms24033022> PMID: 36769340
- [102] Pritam, P.; Deka, R.; Bhardwaj, A.; Srivastava, R.; Kumar, D.; Jha, A.K.; Jha, N.K.; Villa, C.; Jha, S.K. Antioxidants in Alzheimer's disease: Current therapeutic significance and future prospects. *Biology*, **2022**, *11*(2), 212. <http://dx.doi.org/10.3390/biology11020212> PMID: 35205079
- [103] Zhang, Y.; Zhou, C.; Yang, S.; Zhang, Y.; Ye, Z.; He, P.; Liu, M.; Wu, Q.; Qin, X. Association of regular use of ibuprofen and paracetamol, genetic susceptibility, and new-onset dementia in the older population. *Gen. Hosp. Psychiatry*, **2023**, *84*, 226-233. <http://dx.doi.org/10.1016/j.genhosppsych.2023.08.006> PMID: 37633120
- [104] Varrassi, G.; Pergolizzi, J.V.; Dowling, P.; Paladini, A. Ibuprofen safety at the golden anniversary: Are all NSAIDs the same? A narrative review. *Adv. Ther.*, **2020**, *37*(1), 61-82. <http://dx.doi.org/10.1007/s12325-019-01144-9> PMID: 31705437
- [105] Rivers-Auty, J.; Mather, A.E.; Peters, R.; Lawrence, C.B.; Brough, D. Anti-inflammatories in Alzheimer's disease—potential therapy or spurious correlate? *Brain Commun.*, **2020**, *2*(2), fcaa109. <http://dx.doi.org/10.1093/braincomms/fcaa109> PMID: 33134914
- [106] Fisher, E.S.; Curry, S.C. Evaluation and treatment of acetaminophen toxicity. *Adv. Pharmacol.*, **2019**, *85*, 263-272. <http://dx.doi.org/10.1016/bs.apha.2018.12.004> PMID: 31307590
- [107] Sharma, N.; An, S.S.A.; Kim, S.Y. Medication exposure and risk of dementia and Alzheimer's disease. *Int. J. Mol. Sci.*, **2024**, *25*(23), 12850. <http://dx.doi.org/10.3390/ijms252312850> PMID: 39684561
- [108] Deepika; Maurya, P.K. Deepika, Maurya P.K. Health benefits of quercetin in age-related diseases. *Molecules*, **2022**, *27*(8), 2498. <http://dx.doi.org/10.3390/molecules27082498> PMID: 35458696

- [109] Cui, Z.; Zhao, X.; Ameer, F.K.; Du, X.; Wang, Y.; Li, D.; Shu, G.; Tian, Y.; Zhao, X. Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism. *Front. Immunol.*, **2022**, *13*, 943321. <http://dx.doi.org/10.3389/fimmu.2022.943321> PMID: 35935939
- [110] Bayazid, A.B.; Lim, B.O. Quercetin is an active agent in berries against neurodegenerative diseases progression through modulation of Nrf2/HO1. *Nutrients*, **2022**, *14*(23), 5132. <http://dx.doi.org/10.3390/nu14235132> PMID: 36501161
- [111] Alebrahim-Dehkordi, E.; Soveyzi, F.; Arian, A.S.; Hamedanchi, N.F.; Hasanpour-Dehkordi, A.; Rafieian-Kopaei, M. Quercetin and its role in reducing the expression of pro-inflammatory cytokines in osteoarthritis. *Antiinflamm. Antiallergy Agents Med. Chem.*, **2021**, *21*(3), 153-165. <http://dx.doi.org/10.2174/1871523022666221213155905> PMID: 36518039
- [112] Cichon, N.; Grabowska, W.; Gorniak, L.; Stela, M.; Harmata, P.; Ceremuga, M.; Bijak, M. Mechanistic and therapeutic insights into flavonoid-based inhibition of acetylcholinesterase: Implications for neurodegenerative diseases. *Nutrients*, **2024**, *17*(1), 78. <http://dx.doi.org/10.3390/nu17010078> PMID: 39796512
- [113] Luo, X.; Bao, X.; Weng, X.; Bai, X.; Feng, Y.; Huang, J.; Liu, S.; Jia, H.; Yu, B. The protective effect of quercetin on macrophage pyroptosis via TLR2/Myd88/NF- κ B and ROS/AMPK pathway. *Life Sci.*, **2022**, *291*, 120064. <http://dx.doi.org/10.1016/j.lfs.2021.120064> PMID: 34688696
- [114] Ramezani, M.; Meymand, A.Z.; Khodaghali, F.; Kamsorkh, H.M.; Asadi, E.; Noori, M.; Rahimian, K.; Shahrababaki, A.S.; Talebi, A.; Parsaiyan, H.; Shiravand, S.; Darbandi, N. A role for flavonoids in the prevention and/or treatment of cognitive dysfunction, learning, and memory deficits: A review of preclinical and clinical studies. *Nutr. Neurosci.*, **2023**, *26*(2), 156-172. <http://dx.doi.org/10.1080/1028415X.2022.2028058> PMID: 35152858
- [115] Paula, P.C.; Angelica Maria, S.G.; Luis, C.H.; Gloria Patricia, C.G. Preventive effect of quercetin in a triple transgenic Alzheimer's disease mice model. *Molecules*, **2019**, *24*(12), 2287. <http://dx.doi.org/10.3390/molecules24122287> PMID: 31226738
- [116] Sabogal-Guáqueta, A.M.; Muñoz-Manco, J.I.; Ramírez-Pineda, J.R.; Lamprea-Rodríguez, M.; Osorio, E.; Cardona-Gómez, G.P. The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice. *Neuropharmacology*, **2015**, *93*, 134-145. <http://dx.doi.org/10.1016/j.neuropharm.2015.01.027> PMID: 25666032
- [117] Vargas-Restrepo, F.; Sabogal-Guáqueta, A.M.; Cardona-Gómez, G.P. Quercetin ameliorates inflammation in CA1 hippocampal region in aged triple transgenic Alzheimer's disease mice model. *Biomédica*, **2018**, *38*(0), 69-76. <http://dx.doi.org/10.7705/biomedica.v38i0.3761> PMID: 29809330
- [118] Kandemir, K.; Tomas, M.; McClements, D.J.; Capanoglu, E. Recent advances on the improvement of quercetin bioavailability. *Trends Food Sci. Technol.*, **2022**, *119*, 192-200. <http://dx.doi.org/10.1016/j.tifs.2021.11.032>
- [119] Abbas, S.; Latif, M.S.; Shafie, N.S.; Ghazali, M.I.; Kormin, F. Neuroprotective expression of turmeric and curcumin. *Food Res.*, **2020**, *4*(6), 2366-2381. [http://dx.doi.org/10.26656/fr.2017.4\(6\).363](http://dx.doi.org/10.26656/fr.2017.4(6).363)
- [120] Wu, Y.H.; Hsieh, H.L. Roles of heme oxygenase-1 in neuroinflammation and brain disorders. *Antioxidants*, **2022**, *11*(5), 923. <http://dx.doi.org/10.3390/antiox11050923> PMID: 35624787
- [121] Esmaealzadeh, N.; Miri, M.S.; Mavaddat, H.; Peyrovinasab, A.; Ghasemi Zargar, S.; Sirous Kabiri, S.; Razavi, S.M.; Abdolghaffari, A.H. The regulating effect of curcumin on NF- κ B pathway in neurodegenerative diseases: A review of the underlying mechanisms. *Inflammopharmacology*, **2024**, *32*(4), 2125-2151. <http://dx.doi.org/10.1007/s10787-024-01492-1> PMID: 38769198
- [122] Lv, H.; Wang, Y.; Yang, X.; Ling, G.; Zhang, P. Application of curcumin nanoformulations in Alzheimer's disease: Prevention, diagnosis and treatment. *Nutr. Neurosci.*, **2023**, *26*(8), 727-742. <http://dx.doi.org/10.1080/1028415X.2022.2084550> PMID: 35694842
- [123] Björklund, G.; Oliinyk, P.; Khavrona, O.; Lozynska, I.; Lysiuk, R.; Darmohray, R.; Antonyak, H.; Dub, N.; Zayachuk, V.; Antoniv, O.; Rybak, O.; Peana, M. The effects of fisetin and curcumin on oxidative damage caused by transition metals in neurodegenerative diseases. *Mol. Neurobiol.*, **2025**, *62*(1), 1225-1246. <http://dx.doi.org/10.1007/s12035-024-04321-2> PMID: 38970766
- [124] Lunelli, T. Emulsion-based delivery systems to improve gut and brain bioaccessibility of curcumin in relation to Alzheimer's disease prevention. *Theses and Dissertations*, **2023**.
- [125] Jacob, S.; Kather, F.; Morsy, M.; Boddu, S.; Attimarad, M.; Shah, J.; Shinu, P.; Nair, A. Advances in nanocarrier systems for overcoming formulation challenges of curcumin: Current insights. *Nanomaterials*, **2024**, *14*(8), 672. <http://dx.doi.org/10.3390/nano14080672> PMID: 38668166
- [126] Small, G.W.; Siddarth, P.; Li, Z.; Miller, K.J.; Ercoli, L.; Emerson, N.D.; Martinez, J.; Wong, K.P.; Liu, J.; Merrill, D.A.; Chen, S.T.; Henning, S.M.; Satyamurthy, N.; Huang, S.C.; Heber, D.; Barrio, J.R. Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: A double-blind, placebo-controlled 18-month trial. *Am. J. Geriatr. Psychiatry*, **2018**, *26*(3), 266-277. <http://dx.doi.org/10.1016/j.jagp.2017.10.010> PMID: 29246725
- [127] Elawad, M.A.; Ayaz, M.; Mosa, O.F.; Usman, A.; Hamdoon, A.A.E.; Almwash, S.; Salim, L.H.M.; Ahmed, A.; Elkhailifa, M.E.M. Polyphenols and their biogenic nano-formulations targeting BACE1 as anti-amyloid therapies: Meeting the challenges of bioavailability, safety, and specificity for the treatment of Alzheimer's disease. *Mol. Nutr. Food Res.*, **2024**, *68*(24), 2400525. <http://dx.doi.org/10.1002/mnfr.202400525> PMID: 39628325
- [128] Nunes, Y.C.; Mendes, N.M.; Pereira de Lima, E.; Chehadi, A.C.; Lamas, C.B.; Haber, J.F.S.; dos Santos Bueno, M.; Araújo, A.C.; Catharin, V.C.S.; Detregiachi, C.R.P.; Laurindo, L.F.; Tanaka, M.; Barbalho, S.M.; Marin, M.J.S. Curcumin: A golden approach to healthy aging: A systematic review of the evidence. *Nutrients*, **2024**, *16*(16), 2721. <http://dx.doi.org/10.3390/nu16162721> PMID: 39203857
- [129] Gao, L.; Li, X.; Meng, S.; Ma, T.; Wan, L.; Xu, S. Chlorogenic acid alleviates A β 25-35-induced autophagy and cognitive impairment via the mTOR/TFEB signaling pathway. *Drug Des. Devel. Ther.*, **2020**, *14*, 1705-1716. <http://dx.doi.org/10.2147/DDDT.S235969> PMID: 32440096
- [130] Kabir, M.T.; Rahman, M.H.; Shah, M.; Jamiruddin, M.R.; Basak, D.; Al-Harrasi, A.; Bhatia, S.; Ashraf, G.M.; Najda, A.; El-kott, A.F.; Mohamed, H.R.H.; Al-malky, H.S.; Germoush, M.O.; Altayr, A.E.; Alwafai, E.B.; Ghaboura, N.; Abdel-Daim, M.M. Therapeutic promise of carotenoids as antioxidants and anti-inflammatory agents in neurodegenerative disorders. *Biomed. Pharmacother.*, **2022**, *146*, 112610. <http://dx.doi.org/10.1016/j.biopha.2021.112610> PMID: 35062074
- [131] Batool, Z.; Chen, J.H.; Gao, Y.; Lu, L.W.; Xu, H.; Liu, B.; Wang, M.; Chen, F. Natural carotenoids as neuroprotective agents for Alzheimer's disease: An evidence-based comprehensive review. *J. Agric. Food Chem.*, **2022**, *70*(50), 15631-15646. <http://dx.doi.org/10.1021/acs.jafc.2c06206> PMID: 36480951
- [132] Yap, H.M.; Lye, K.L. An insight of vitamin E as neuroprotective agents. *Prog. Microbes Mol. Biol.*, **2020**, *3*(1). <http://dx.doi.org/10.36877/pmm.b.a0000071>
- [133] Browne, D.; McGuinness, B.; Woodside, J.V.; McKay, G.J. Vitamin E and Alzheimer's disease: What do we know so far? *Clin. Interv. Aging*, **2019**, *14*, 1303-1317. <http://dx.doi.org/10.2147/CIA.S186760> PMID: 31409980
- [134] Joe, E.; Ringman, J.M. Cognitive symptoms of Alzheimer's disease:

- Clinical management and prevention. *BMJ*, **2019**, 367, l6217. <http://dx.doi.org/10.1136/bmj.l6217> PMID: 31810978
- [135] Jia, J.; Hu, J.; Huo, X.; Miao, R.; Zhang, Y.; Ma, F. Effects of vitamin D supplementation on cognitive function and blood A β -related biomarkers in older adults with Alzheimer's disease: A randomised, double-blind, placebo-controlled trial. *J. Neurol. Neurosurg. Psychiatry*, **2019**, 90(12), jnnp-2018-320199. <http://dx.doi.org/10.1136/jnnp-2018-320199> PMID: 31296588
- [136] Mayne, P.E.; Burne, T.H.J. Vitamin D in synaptic plasticity, cognitive function, and neuropsychiatric illness. *Trends Neurosci.*, **2019**, 42(4), 293-306. <http://dx.doi.org/10.1016/j.tins.2019.01.003> PMID: 30795846
- [137] Olaso-Gonzalez, G.; Inzitari, M.; Bellelli, G.; Morandi, A.; Barcons, N.; Viña, J. Impact of supplementation with vitamins B $_6$, B $_{12}$, and/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impairment: A systematic review. *IUBMB Life*, **2022**, 74(1), 74-84. <http://dx.doi.org/10.1002/iub.2507> PMID: 34058062
- [138] Wu, Y.; Smith, A.D.; Refsum, H.; Kwok, T. Effectiveness of B vitamins and their interactions with aspirin in improving cognitive functioning in older people with mild cognitive impairment: Pooled post-hoc analyses of two randomized trials. *J. Nutr. Health Aging*, **2021**, 25(10), 1154-1160. <http://dx.doi.org/10.1007/s12603-021-1708-1> PMID: 34866142
- [139] Truong, V.L.; Jun, M.; Jeong, W.S. Role of resveratrol in regulation of cellular defense systems against oxidative stress. *Biofactors*, **2018**, 44(1), 36-49. <http://dx.doi.org/10.1002/biof.1399> PMID: 29193412
- [140] Bartra, C.; Yuan, Y.; Vuraić, K.; Valdés-Quiroz, H.; Garcia-Baucells, P.; Slevin, M.; Pastorello, Y.; Suñol, C.; Sanfeliu, C. Resveratrol activates antioxidant protective mechanisms in cellular models of Alzheimer's disease inflammation. *Antioxidants*, **2024**, 13(2), 177. <http://dx.doi.org/10.3390/antiox13020177> PMID: 38397775
- [141] Islam, F.; Nafady, M.H.; Islam, M.R.; Saha, S.; Rashid, S.; Akter, A.; Or-Rashid, M.H.; Akhtar, M.F.; Perveen, A.; Md Ashraf, G.; Rahman, M.H.; Hussein Sweilam, S. Resveratrol and neuroprotection: An insight into prospective therapeutic approaches against Alzheimer's disease from bench to bedside. *Mol. Neurobiol.*, **2022**, 59(7), 4384-4404. <http://dx.doi.org/10.1007/s12035-022-02859-7> PMID: 35545730
- [142] Buglio, D.S.; Marton, L.T.; Laurindo, L.F.; Guiguer, E.L.; Araújo, A.C.; Buchaim, R.L.; Goulart, R.A.; Rubira, C.J.; Barbalho, S.M. The role of resveratrol in mild cognitive impairment and Alzheimer's disease: A systematic review. *J. Med. Food*, **2022**, 25(8), 797-806. <http://dx.doi.org/10.1089/jmf.2021.0084> PMID: 35353606
- [143] Adewale, G.G.; Olajide, P.A.; Omowumi, O.S.; Okunlola, D.D.; Taiwo, A.M.; Adetuyi, B.O. Toxicological significance of the occurrence of selenium in foods. *World News Nat. Sci.*, **2022**, 44, 63-88.
- [144] Birmann, P.T.; Casaril, A.M.; Abenante, L.; Penteado, F.; Brünig, C.A.; Savegnago, L.; Lenardão, E.J. Neuropharmacology of organoselenium compounds in mental disorders and degenerative diseases. *Curr. Med. Chem.*, **2023**, 30(21), 2357-2395. <http://dx.doi.org/10.2174/0929867329666220615124412> PMID: 35708081
- [145] Barbosa, F.A.R.; Canto, R.F.S.; Teixeira, K.F.; de Souza, A.S.; de Oliveira, A.S.; Braga, A.L. Selenium-derivative compounds: A review of new perspectives in the treatment of Alzheimer's disease. *Curr. Med. Chem.*, **2023**, 30(6), 689-700. <http://dx.doi.org/10.2174/0929867329666220224161454> PMID: 35209817
- [146] Pyka, P.; Garbo, S.; Fioravanti, R.; Jacob, C.; Hittinger, M.; Handzlik, J.; Zwergel, C.; Battistelli, C. Selenium-containing compounds: A new hope for innovative treatments in Alzheimer's disease and Parkinson's disease. *Drug Discov. Today*, **2024**, 29(8), 104062. <http://dx.doi.org/10.1016/j.drudis.2024.104062> PMID: 38871111
- [147] Ramli, F.F.; Cowen, P.J.; Godlewska, B.R. The potential use of ebsselen in treatment-resistant depression. *Pharmaceuticals*, **2022**, 15(4), 485. <http://dx.doi.org/10.3390/ph15040485> PMID: 35455482
- [148] Arslan, N.; Bozkır, E.; Koçak, T.; Akin, M.; Yılmaz, B. From garden to pillow: Understanding the relationship between plant-based nutrition and quality of sleep. *Nutrients*, **2024**, 16(16), 2683. <http://dx.doi.org/10.3390/nu16162683> PMID: 39203818
- [149] Potes, Y.; Díaz-Luis, A.; Bermejo-Millo, J.C.; Pérez-Martínez, Z.; de Luxán-Delgado, B.; Rubio-González, A.; Menéndez-Valle, I.; Gutiérrez-Rodríguez, J.; Solano, J.J.; Caballero, B.; Vega-Naredo, I.; Coto-Montes, A. Melatonin alleviates the impairment of muscle bioenergetics and protein quality control systems in leptin-deficiency-induced obesity. *Antioxidants*, **2023**, 12(11), 1962. <http://dx.doi.org/10.3390/antiox12111962> PMID: 38001815
- [150] Singh, A.K.; Singla, R.K.; Pandey, A.K. Chlorogenic acid: A dietary phenolic acid with promising pharmacotherapeutic potential. *Curr. Med. Chem.*, **2023**, 30(34), 3905-3926. <http://dx.doi.org/10.2174/0929867329666220816154634> PMID: 35975861
- [151] Roy, J.; Wong, K.Y.; Aquili, L.; Uddin, M.S.; Heng, B.C.; Tipoe, G.L.; Wong, K.H.; Fung, M.L.; Lim, L.W. Role of melatonin in Alzheimer's disease: From preclinical studies to novel melatonin-based therapies. *Front. Neuroendocrinol.*, **2022**, 65, 100986. <http://dx.doi.org/10.1016/j.yfrne.2022.100986> PMID: 35167824
- [152] Wade, A.G.; Farmer, M.; Harari, G.; Fund, N.; Laudon, M.; Nir, T.; Frydman-Marom, A.; Zisapel, N. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: A 6-month, randomized, placebo-controlled, multicenter trial. *Clin. Interv. Aging*, **2014**, 9, 947-961. <http://dx.doi.org/10.2147/CIA.S65625> PMID: 24971004
- [153] Mihailović, V.; Srećković, N.; Popović-Djordjević, J.B. Silybin and Silymarin: Phytochemistry, bioactivity, and pharmacology. In: *Handbook of Dietary Flavonoids*; Springer: Cham, **2023**; pp. 1-45. http://dx.doi.org/10.1007/978-3-030-94753-8_20-1
- [154] Liu, Y.; Wu, M.; Ren, M.; Bao, H.; Wang, Q.; Wang, N.; Sun, S.; Xu, J.; Yang, X.; Zhao, X.; Bao, Y.; He, G.; Xu, W. From medical herb to functional food: Development of a fermented milk containing silybin and protein from milk thistle. *Foods*, **2023**, 12(6), 1308. <http://dx.doi.org/10.3390/foods12061308> PMID: 36981234
- [155] Singh, N.K.; Bhushan, B. Preclinical evidence-based neuroprotective potential of silibinin. *Curr. Drug Res. Rev.*, **2024**, 16(1), 43-56. <http://dx.doi.org/10.2174/2589977515666230327154800>
- [156] Bai, D.; Jin, G.; Zhang, D.; Zhao, L.; Wang, M.; Zhu, Q.; Zhu, L.; Sun, Y.; Liu, X.; Chen, X.; Zhang, L.; Li, W.; Cui, Y. Natural silibinin modulates amyloid precursor protein processing and amyloid- β protein clearance in APP/PS1 mice. *J. Physiol. Sci.*, **2019**, 69(4), 643-652. <http://dx.doi.org/10.1007/s12576-019-00682-9> PMID: 31087219
- [157] Ashique, S.; Mohanto, S.; Kumar, N.; Nag, S.; Mishra, A.; Biswas, A.; Rihan, M.; Srivastava, S.; Bhowmick, M.; Taghizadeh-Hesary, F. Unlocking the possibilities of therapeutic potential of silymarin and silibinin against neurodegenerative Diseases-A mechanistic overview. *Eur. J. Pharmacol.*, **2024**, 981, 176906. <http://dx.doi.org/10.1016/j.ejphar.2024.176906> PMID: 39154829
- [158] Caruso, G.; Godos, J.; Privitera, A.; Lanza, G.; Castellano, S.; Chillemi, A.; Bruni, O.; Ferri, R.; Caraci, F.; Grosso, G. Phenolic acids and prevention of cognitive decline: Polyphenols with a neuroprotective role in cognitive disorders and Alzheimer's disease. *Nutrients*, **2022**, 14(4), 819. <http://dx.doi.org/10.3390/nu14040819> PMID: 35215469
- [159] Rossi, S.L.; Subramanian, P.; Bovenkamp, D.E. The future is precision medicine-guided diagnoses, preventions and treatments for neurodegenerative diseases. *Front. Aging Neurosci.*, **2023**, 15, 1128619. <http://dx.doi.org/10.3389/fnagi.2023.1128619> PMID: 37009453
- [160] Arafah, A.; Khatoon, S.; Rasool, I.; Khan, A.; Rather, M.A.; Abujabal, K.A.; Faqih, Y.A.H.; Rashid, H.; Rashid, S.M.; Bilal

- Ahmad, S.; Alexiou, A.; Rehman, M.U. The future of precision medicine in the cure of Alzheimer's disease. *Biomedicines*, **2023**, *11*(2), 335.
<http://dx.doi.org/10.3390/biomedicines11020335> PMID: 36830872
- [161] Bezerra, J.R.; de Souza Nascimento, T.; Tavares, J.; de Aguiar, M.S.S.; Maia, M.V.V.; de Andrade, G.M. Neuroprotective effect of chlorogenic acid in an animal model of sporadic Alzheimer's disease induced by streptozotocin. *Mol. Neurobiol.*, **2025**, *62*(1), 674-692.
<http://dx.doi.org/10.1007/s12035-024-04299-x> PMID: 38898198
- [162] Shi, D.; Hao, Z.; Qi, W.; Jiang, F.; Liu, K.; Shi, X. Aerobic exercise combined with chlorogenic acid exerts neuroprotective effects and reverses cognitive decline in Alzheimer's disease model mice (APP/PS1) via the SIRT1/PGC-1 α /PPAR γ signaling pathway. *Front. Aging Neurosci.*, **2023**, *15*, 1269952.
<http://dx.doi.org/10.3389/fnagi.2023.1269952> PMID: 38046466
- [163] Zeng, L.; Xiang, R.; Fu, C.; Qu, Z.; Liu, C. The Regulatory effect of chlorogenic acid on gut-brain function and its mechanism: A systematic review. *Biomed. Pharmacother.*, **2022**, *149*, 112831.
<http://dx.doi.org/10.1016/j.biopha.2022.112831> PMID: 35303566
- [164] Heitman, E.; Ingram, D.K. Cognitive and neuroprotective effects of chlorogenic acid. *Nutr. Neurosci.*, **2017**, *20*(1), 32-39.
<http://dx.doi.org/10.1179/1476830514Y.0000000146> PMID: 25130715
- [165] Guasch-Ferré, M.; Willett, W.C. The Mediterranean diet and health: A comprehensive overview. *J. Intern. Med.*, **2021**, *290*(3), 549-566.
<http://dx.doi.org/10.1111/joim.13333> PMID: 34423871
- [166] Franco, G.A.; Interdonato, L.; Cordaro, M.; Cuzzocrea, S.; Di Paola, R. Bioactive compounds of the Mediterranean diet as nutritional support to fight neurodegenerative disease. *Int. J. Mol. Sci.*, **2023**, *24*(8), 7318.
<http://dx.doi.org/10.3390/ijms24087318> PMID: 37108480
- [167] Mukherjee, M.S.; Han, C.Y.; Sukumaran, S.; Delaney, C.L.; Miller, M.D. Effect of anti-inflammatory diets on inflammation markers in adult human populations: A systematic review of randomized controlled trials. *Nutr. Rev.*, **2022**, *81*(1), 55-74.
<http://dx.doi.org/10.1093/nutrit/nuac045> PMID: 35831971
- [168] Martínez-Lapiscina, E.H.; Clavero, P.; Toledo, E.; Estruch, R.; Salas-Salvado, J.; San Julián, B.; Sanchez-Tainta, A.; Ros, E.; Valls-Pedret, C.; Martínez-González, M.Á. Mediterranean diet improves cognition: The PREDIMED-NAVARRA randomised trial. *J. Neurol. Neurosurg. Psychiatry*, **2013**, *84*(12), 1318-1325.
<http://dx.doi.org/10.1136/jnnp-2012-304792> PMID: 23670794
- [169] Valls-Pedret, C.; Sala-Vila, A.; Serra-Mir, M.; Corella, D.; de la Torre, R.; Martínez-González, M.Á.; Martínez-Lapiscina, E.H.; Fitó, M.; Pérez-Heras, A.; Salas-Salvado, J.; Estruch, R.; Ros, E. Mediterranean diet and age-related cognitive decline: A randomized clinical trial. *JAMA Intern. Med.*, **2015**, *175*(7), 1094-1103.
<http://dx.doi.org/10.1001/jamainternmed.2015.1668> PMID: 25961184
- [170] Ferretti, M.T.; Iulita, M.F.; Cavedo, E.; Chiesa, P.A.; Schumacher Dimech, A.; Santuccione Chadha, A.; Baracchi, F.; Girouard, H.; Misoch, S.; Giacobini, E.; Depypere, H.; Hampel, H. Sex differences in Alzheimer disease — the gateway to precision medicine. *Nat. Rev. Neurol.*, **2018**, *14*(8), 457-469.
<http://dx.doi.org/10.1038/s41582-018-0032-9> PMID: 29985474
- [171] Fitzpatrick, D.; Blanco-Campal, A.; Kyne, L. A case of overlap posterior cortical atrophy and logopenic variant primary progressive aphasia. *Neurologist*, **2019**, *24*(2), 62-65.
<http://dx.doi.org/10.1097/NRL.0000000000000225> PMID: 30817493
- [172] Ramanan, S.; Irish, M.; Patterson, K.; Rowe, J.B.; Gorno-Tempini, M.L.; Lambon Ralph, M.A. Understanding the multidimensional cognitive deficits of logopenic variant primary progressive aphasia. *Brain*, **2022**, *145*(9), 2955-2966.
<http://dx.doi.org/10.1093/brain/awac208> PMID: 35857482
- [173] Tort-Merino, A.; Falgás, N.; Allen, I.E.; Balasa, M.; Olives, J.; Contador, J.; Castellví, M.; Juncà-Parella, J.; Guillén, N.; Borrego-Écija, S.; Bosch, B.; Fernández-Villullas, G.; Ramos-Campoy, O.; Antonell, A.; Rami, L.; Sánchez-Valle, R.; Lladó, A. Early-onset Alzheimer's disease shows a distinct neuropsychological profile and more aggressive trajectories of cognitive decline than late-onset. *Ann. Clin. Transl. Neurol.*, **2022**, *9*(12), 1962-1973.
<http://dx.doi.org/10.1002/acn3.51689> PMID: 36398437
- [174] Bhatti, G.K.; Reddy, A.P.; Reddy, P.H.; Bhatti, J.S. Lifestyle modifications and nutritional interventions in aging-associated cognitive decline and Alzheimer's disease. *Front. Aging Neurosci.*, **2020**, *11*, 369.
<http://dx.doi.org/10.3389/fnagi.2019.00369> PMID: 31998117
- [175] Jackson, R.J.; Hyman, B.T.; Serrano-Pozo, A. Multifaceted roles of APOE in Alzheimer disease. *Nat. Rev. Neurol.*, **2024**, *20*(8), 457-474.
<http://dx.doi.org/10.1038/s41582-024-00988-2> PMID: 38906999
- [176] Bhilare, N.V.; Marulkar, V.S.; Kumar, D.; Chatap, V.K.; Patil, K.S.; Shirote, P.J. An insight into prodrug strategy for the treatment of Alzheimer's disease. *Med. Chem. Res.*, **2022**, *31*(3), 383-399.
<http://dx.doi.org/10.1007/s00044-022-02859-1>
- [177] Uddin, M.S.; Al Mamun, A.; Kabir, M.T.; Ahmad, J.; Jeandet, P.; Sarwar, M.S.; Ashraf, G.M.; Aleya, L. Neuroprotective role of polyphenols against oxidative stress-mediated neurodegeneration. *Eur. J. Pharmacol.*, **2020**, *886*, 173412.
<http://dx.doi.org/10.1016/j.ejphar.2020.173412> PMID: 32771668
- [178] Sharma, M.; Pal, P.; Gupta, S.K. Advances in Alzheimer's disease: A multifaceted review of potential therapies and diagnostic techniques for early detection. *Neurochem. Int.*, **2024**, *177*, 105761.
<http://dx.doi.org/10.1016/j.neuint.2024.105761> PMID: 38723902
- [179] Touns, K.; Hathaway, A.; Gordon, D.; Chung, H.; Raji, C.; Boyd, A.; Hill, B.D.; Hausman-Cohen, S.; Attarha, M.; Chwa, W.J.; Jarrett, M.; Bredesen, D.E. Precision medicine approach to Alzheimer's disease: Successful pilot project. *J. Alzheimers Dis.*, **2022**, *88*(4), 1411-1421.
<http://dx.doi.org/10.3233/JAD-215707> PMID: 35811518
- [180] Salehi, B.; Calina, D.; Docea, A.; Koirala, N.; Aryal, S.; Lombardo, D.; Pasqua, L.; Taheri, Y.; Marina Salgado Castillo, C.; Martorell, M.; Martins, N.; Iriti, M.; Suleria, H.; Sharifi-Rad, J. Curcumin's nanomedicine formulations for therapeutic application in neurological diseases. *J. Clin. Med.*, **2020**, *9*(2), 430.
<http://dx.doi.org/10.3390/jcm9020430> PMID: 32033365
- [181] Liu, N.; Ruan, J.; Li, H.; Fu, J. Nanoparticles loaded with natural medicines for the treatment of Alzheimer's disease. *Front. Neurosci.*, **2023**, *17*, 1112435.
<http://dx.doi.org/10.3389/fnins.2023.1112435> PMID: 37877008
- [182] Küpeli Akkol, E.; Bardakci, H.; Yücel, Ç.; Şeker Karatoprak, G.; Karpuz, B.; Khan, H. A new perspective on the treatment of Alzheimer's disease and sleep deprivation-related consequences: Can curcumin help? *Oxid. Med. Cell. Longev.*, **2022**, *2022*(1), 6168199.
<http://dx.doi.org/10.1155/2022/6168199> PMID: 35069976
- [183] Minocha, T.; Birla, H.; Obaid, A.A.; Rai, V.; Sushma, P.; Shivamallu, C.; Moustafa, M.; Al-Shehri, M.; Al-Emam, A.; Tikhonova, M.A.; Yadav, S.K.; Poeggeler, B.; Singh, D.; Singh, S.K. Flavonoids as promising neuroprotectants and their therapeutic potential against Alzheimer's disease. *Oxid. Med. Cell. Longev.*, **2022**, *2022*(1), 6038996.
<http://dx.doi.org/10.1155/2022/6038996> PMID: 36071869
- [184] Nishihira, J.; Nishimura, M.; Kurimoto, M.; Kagami-Katsuyama, H.; Hattori, H.; Nakagawa, T.; Muro, T.; Kobori, M. The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: A randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial. *J. Clin. Biochem. Nutr.*, **2021**, *69*(2), 203-215.
<http://dx.doi.org/10.3164/jcbs.21-17> PMID: 34616111
- [185] Millar, C.L.; Iloputaife, I.; Baldyga, K.; Norling, A.M.; Boulougoura, A.; Vichos, T.; Tchkonja, T.; Deisinger, A.; Pirtskhalava, T.; Kirkland, J.L.; Trivison, T.G.; Lipsitz, L.A. A pilot

- study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease. *EBioMedicine*, **2025**, 113, 105612.
<http://dx.doi.org/10.1016/j.ebiom.2025.105612> PMID: 40010154
- [186] Wang, W.; Zhao, R.; Liu, B.; Li, K. The effect of curcumin supplementation on cognitive function: An updated systematic review and meta-analysis. *Front. Nutr.*, **2025**, 12, 1549509.
<http://dx.doi.org/10.3389/fnut.2025.1549509> PMID: 40308636
- [187] Jin, S.; Guan, X.; Min, D. Evidence of clinical efficacy and pharmacological mechanisms of resveratrol in the treatment of Alzheimer's disease. *Curr. Alzheimer Res.*, **2023**, 20(8), 588-602.
<http://dx.doi.org/10.2174/0115672050272577231120060909> PMID: 38047366
- [188] Puranik, N.; Kumari, M.; Tiwari, S.; Dhakal, T.; Song, M. Resveratrol as a therapeutic agent in Alzheimer's disease: Evidence from clinical studies. *Nutrients*, **2025**, 17(15), 2557.
<http://dx.doi.org/10.3390/nu17152557> PMID: 40806141
- [189] Lopresti, A.L.; Smith, S.J.; Drummond, P.D. The effects of lutein and zeaxanthin supplementation on cognitive function in adults with self-reported mild cognitive complaints: A randomized, double-blind, placebo-controlled study. *Front. Nutr.*, **2022**, 9, 843512.
<http://dx.doi.org/10.3389/fnut.2022.843512> PMID: 35252311
- [190] Wang, L.; Zhao, T.; Zhu, X.; Jiang, Q. Low blood carotenoid status in dementia and mild cognitive impairment: A systematic review and meta-analysis. *BMC Geriatr.*, **2023**, 23(1), 195.
<http://dx.doi.org/10.1186/s12877-023-03900-7> PMID: 36997905
- [191] Zhao, R.; Han, X.; Zhang, H.; Liu, J.; Zhang, M.; Zhao, W.; Jiang, S.; Li, R.; Cai, H.; You, H. Association of vitamin E intake in diet and supplements with risk of dementia: A meta-analysis. *Front. Aging Neurosci.*, **2022**, 14, 955878.
<http://dx.doi.org/10.3389/fnagi.2022.955878> PMID: 35978949
- [192] Dysken, M.W.; Sano, M.; Asthana, S.; Vertrees, J.E.; Pallaki, M.; Llorente, M.; Love, S.; Schellenberg, G.D.; McCarten, J.R.; Malphurs, J.; Prieto, S.; Chen, P.; Loreck, D.J.; Trapp, G.; Bakshi, R.S.; Mintzer, J.E.; Heidebrink, J.L.; Vidal-Cardona, A.; Arroyo, L.M.; Cruz, A.R.; Zachariah, S.; Kowall, N.W.; Chopra, M.P.; Craft, S.; Thielke, S.; Turvey, C.L.; Woodman, C.; Monnell, K.A.; Gordon, K.; Tomaska, J.; Segal, Y.; Peduzzi, P.N.; Guarino, P.D. Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. *JAMA*, **2014**, 311(1), 33-44.
<http://dx.doi.org/10.1001/jama.2013.282834> PMID: 24381967
- [193] Wang, Z.; Zhu, W.; Xing, Y.; Jia, J.; Tang, Y. B vitamins and prevention of cognitive decline and incident dementia: A systematic review and meta-analysis. *Nutr. Rev.*, **2022**, 80(4), 931-949.
<http://dx.doi.org/10.1093/nutrit/nuab057> PMID: 34432056
- [194] Zhang, Z.; Xue, P.; Bendlin, B.B.; Zetterberg, H.; De Felice, F.; Tan, X.; Benedict, C. Melatonin: A potential nighttime guardian against Alzheimer's. *Mol. Psychiatry*, **2025**, 30(1), 237-250.
<http://dx.doi.org/10.1038/s41380-024-02691-6> PMID: 39128995
- [195] Samanta, S.; Akhter, F.; Roy, A.; Chen, D.; Turner, B.; Wang, Y.; Clemente, N.; Wang, C.; Swerdlow, R.H.; Battaile, K.P.; Lovell, S.; Yan, S.F.; Yan, S.S. New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer's disease. *Brain*, **2024**, 147(5), 1710-1725.
<http://dx.doi.org/10.1093/brain/awad432> PMID: 38146639
- [196] Johal, K.; Jones, D.J.; Bell, L.; Lovegrove, J.A.; Lampert, D.J. Impact of coffee-derived chlorogenic acid on cognition: A systematic review and meta-analysis. *Nutr. Res. Rev.*, **2024**, ••, 1-4.
PMID: 39403843
- [197] Nucci, D.; Sommariva, A.; Degoni, L.M.; Gallo, G.; Mancarella, M.; Natorelli, F.; Savoia, A.; Catalini, A.; Ferranti, R.; Pregliasco, F.E.; Castaldi, S.; Gianfredi, V. Association between Mediterranean diet and dementia and Alzheimer disease: A systematic review with meta-analysis. *Aging Clin. Exp. Res.*, **2024**, 36(1), 77.
<http://dx.doi.org/10.1007/s40520-024-02718-6> PMID: 38519775
- [198] Fekete, M.; Varga, P.; Ungvari, Z.; Fekete, J.T.; Buda, A.; Szappanos, A.; Lehoczki, A.; Mózes, N.; Grosso, G.; Godos, J.; Menyhart, O.; Munkácsy, G.; Tarantini, S.; Yabluchanskiy, A.; Ungvari, A.; Györfy, B. The role of the Mediterranean diet in reducing the risk of cognitive impairment, dementia, and Alzheimer's disease: A meta-analysis. *Geroscience*, **2025**, 47(3), 3111-3130.
<http://dx.doi.org/10.1007/s11357-024-01488-3> PMID: 39797935
- [199] Barnes, L.L.; Dhana, K.; Liu, X.; Carey, V.J.; Ventrelle, J.; Johnson, K.; Hollings, C.S.; Bishop, L.; Laranjo, N.; Stubbs, B.J.; Reilly, X.; Agarwal, P.; Zhang, S.; Grodstein, F.; Tangney, C.C.; Holland, T.M.; Aggarwal, N.T.; Arfanakis, K.; Morris, M.C.; Sacks, F.M. Trial of the MIND diet for prevention of cognitive decline in older persons. *N. Engl. J. Med.*, **2023**, 389(7), 602-611.
<http://dx.doi.org/10.1056/NEJMoa2302368> PMID: 37466280
- [200] Zaplatka, E.; Bule, M.; Shah, S.Z.A.; Uddin, M.S.; Niaz, K. Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer's disease. *Life Sci.*, **2019**, 224, 109-119.
<http://dx.doi.org/10.1016/j.lfs.2019.03.055> PMID: 30914316
- [201] Olayinka, E.; Ore, A.; Adeyemo, O.; Ola, O.; Olotu, O.; Echebiri, R. Quercetin, a flavonoid antioxidant, ameliorated procarbazine-induced oxidative damage to murine tissues. *Antioxidants*, **2015**, 4(2), 304-321.
<http://dx.doi.org/10.3390/antiox4020304> PMID: 26783707
- [202] Chiang, M.C.; Tsai, T.Y.; Wang, C.J. The potential benefits of quercetin for brain health: A review of anti-inflammatory and neuroprotective mechanisms. *Int. J. Mol. Sci.*, **2023**, 24(7), 6328.
<http://dx.doi.org/10.3390/ijms24076328> PMID: 37047299
- [203] Karati, D.; Meur, S.; Roy, S.; Mukherjee, S.; Debnath, B.; Jha, S.K.; Sarkar, B.K.; Naskar, S.; Ghosh, P. Glycogen synthase kinase 3 (GSK3) inhibition: A potential therapeutic strategy for Alzheimer's disease. *Naunyn Schmiedeberg's Arch. Pharmacol.*, **2024**, 398(3), 2319-2342.
<http://dx.doi.org/10.1007/s00210-024-03500-1> PMID: 39432068
- [204] Alizadeh, A.; Pourfallah-Taft, Y.; Khoshnazar, M.; Safdari, A.; Komari, S.V.; Zanganeh, M.; Sami, N.; Valizadeh, M.; Faridzadeh, A.; Alijanzadeh, D.; Mazhari, S.A.; Khademi, R.; Kheirandish, A.; Naziri, M. Flavonoids against depression: A comprehensive review of literature. *Front. Pharmacol.*, **2024**, 15, 1411168.
<http://dx.doi.org/10.3389/fphar.2024.1411168> PMID: 39478958
- [205] Klimova, B.; Kuca, K. Multi-nutrient dietary intervention approach to the management of Alzheimer's disease-A mini-review. *Curr. Alzheimer Res.*, **2016**, 13(12), 1312-1318.
<http://dx.doi.org/10.2174/1567205013666160603000623> PMID: 27335038
- [206] Piccialli, I.; Tedeschi, V.; Caputo, L.; D'Errico, S.; Ciccone, R.; De Feo, V.; Secondo, A.; Pannaccione, A. Exploring the therapeutic potential of phytochemicals in Alzheimer's disease: Focus on polyphenols and monoterpenes. *Front. Pharmacol.*, **2022**, 13, 876614.
<http://dx.doi.org/10.3389/fphar.2022.876614> PMID: 35600880
- [207] Andrade, S.; Ramalho, M.J.; Loureiro, J.A.; Pereira, M.C. Natural compounds for Alzheimer's disease therapy: A systematic review of preclinical and clinical studies. *Int. J. Mol. Sci.*, **2019**, 20(9), 2313.
<http://dx.doi.org/10.3390/ijms20092313> PMID: 31083327
- [208] Cichon, N.; Dziedzic, A.; Gorniak, L.; Miller, E.; Bijak, M.; Starosta, M.; Saluk-Bijak, J. Unusual bioactive compounds with antioxidant properties in adjuvant therapy supporting cognition impairment in age-related neurodegenerative disorders. *Int. J. Mol. Sci.*, **2021**, 22(19), 10707.
<http://dx.doi.org/10.3390/ijms221910707> PMID: 34639048
- [209] Ogunsuyi, O.B.; Ogunruku, O.O.; Umar, H.I.; Obboh, G. Effect of curcumin-donepezil combination on spatial memory, astrocyte activation, and cholinesterase expressions in brain of scopolamine-treated rats. *Mol. Biol. Rep.*, **2024**, 51(1), 864.
<http://dx.doi.org/10.1007/s11033-024-09712-1> PMID: 39073463
- [210] Sharifi-Rad, J.; Rapposelli, S.; Sestito, S.; Herrera-Bravo, J.; Arancibia-Diaz, A.; Salazar, L.A.; Yeskaliyeva, B.; Beyatli, A.

Leyva-Gómez, G.; González-Contreras, C.; Güreş, E.S.; Martorell, M.; Calina, D. Multi-target mechanisms of phytochemicals in Alzheimer's disease: Effects on oxidative stress,

neuroinflammation and protein aggregation. *J. Pers. Med.*, **2022**, *12*(9), 1515.
<http://dx.doi.org/10.3390/jpm12091515> PMID: 36143299

DISCLAIMER: The above article has been published, as is, ahead-of-print, to provide early visibility but is not the final version. Major publication processes like copyediting, proofing, typesetting and further review are still to be done and may lead to changes in the final published version, if it is eventually published. All legal disclaimers that apply to the final published article also apply to this ahead-of-print version.